iCAD (ICAD) 10-K13 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 06, 2015	Jun. 28, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	ICAD
Entity Registrant Name	ICAD INC
Entity Central Index Key	749660
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		15,635,282
Entity Public Float			$85,718,366

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$32,220	$11,880
Trade accounts receivable, net of allowance for doubtful accounts of $203 in 2014 and $73 in 2013	9,642	7,623
Inventory, net	2,214	1,891
Prepaid expenses and other current assets	540	649
Total current assets	44,616	22,043
Property and equipment:
Equipment	8,430	5,245
Leasehold improvements	62	108
Furniture and fixtures	293	283
Marketing assets	331	300
Total property and equipment	9,116	5,936
Less accumulated depreciation and amortization	4,861	4,265
Net property and equipment	4,255	1,671
Other assets:
Other assets	132	419
Intangible assets, net of accumulated amortization of $14,738 in 2014 and $12,468 in 2013	17,504	13,674
Goodwill	27,263	21,109
Total other assets	44,899	35,202
Total assets	93,770	58,916
Current liabilities:
Accounts payable	2,151	2,000
Accrued expenses	5,554	3,799
Interest payable	180	483
Notes and capital lease payable, short-term portion	5,044	3,878
Warrant liability		3,986
Deferred revenue	9,120	8,306
Total current liabilities	22,049	22,452
Other long-term liabilities	51	68
Deferred revenue, long-term portion	1,525	1,726
Settlement costs, long-term portion	744	1,288
Capital lease-long-term portion	1,020	235
Notes payable, long-term portion	5,602	11,770
Total liabilities	30,991	37,539
Commitments and contingencies (Notes 2 and 8)
Stockholders' equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.
Common stock, $ .01 par value: authorized 20,000,000 shares; issued 15,732,177 in 2014 and 11,084,119 in 2013; outstanding 15,546,346 in 2014 and 10,898,288 in 2013	157	111
Additional paid-in capital	209,100	166,735
Accumulated deficit	-145,063	-144,054
Treasury stock at cost, 185,831 shares in 2014 and 2013	-1,415	-1,415
Total stockholders' equity	62,779	21,377
Total liabilities and stockholders' equity	$93,770	$58,916

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$203	$73
Intangible assets, accumulated amortization	$14,738	$12,468
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	15,732,177	11,084,119
Common stock, shares outstanding	15,546,346	10,898,288
Treasury stock, shares	185,831	185,831

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
Products	$18,683	$18,536	$17,233
Service and supplies	25,241	14,531	11,042
Total revenue	43,924	33,067	28,275
Cost of Revenue:
Products	4,912	4,668	3,730
Service and supplies	6,000	4,009	3,188
Amortization and depreciation	1,785	1,305	1,326
Total cost of revenue	12,697	9,982	8,244
Gross profit	31,227	23,085	20,031
Operating expenses:
Engineering and product development	8,159	7,043	7,031
Marketing and sales	12,468	10,328	10,584
General and administrative	8,044	6,365	6,359
Amortization and depreciation	1,741	1,125	1,469
Total operating expenses	30,412	24,861	25,443
Income (loss) from operations	815	-1,776	-5,412
Other (expense) income:
Interest expense	-2,640	-3,277	-3,415
Gain (loss) from change in fair value of warrant liability	1,835	-2,448	-539
Loss from extinguishment of debt	-903
Interest income	37	19	35
Other expense, net	-1,671	-5,706	-3,919
Loss before income tax expense	-856	-7,482	-9,331
Income tax expense	153	126	43
Net loss and comprehensive loss	($1,009)	($7,608)	($9,374)
Net loss per share:
Basic	($0.07)	($0.70)	($0.87)
Diluted	($0.07)	($0.70)	($0.87)
Weighted average number of shares used in computing loss per share:
Basic	14,096	10,842	10,796
Diluted	14,096	10,842	10,796

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2011	$36,055	$110	$164,432	($127,072)	($1,415)
Beginning Balance, shares at Dec. 31, 2011		10,950,902
Issuance of common stock relative to vesting of restricted stock, net of 4,789, 5,249 and 9,904 shares forfeited for tax obligations in 2012, 2013 and 2014 respectively	-12		-12
Issuance of common stock relative to vesting of restricted stock, net of 4,789, 5,249 and 9,904 shares forfeited for tax obligations in 2012, 2013 and 2014 respectively, shares		43,031
Stock-based compensation	996		996
Net income (loss)	-9,374			-9,374
Ending Balance at Dec. 31, 2012	27,665	110	165,416	-136,446	-1,415
Ending Balance, shares at Dec. 31, 2012		10,993,933
Issuance of common stock relative to vesting of restricted stock, net of 4,789, 5,249 and 9,904 shares forfeited for tax obligations in 2012, 2013 and 2014 respectively	-28		-28
Issuance of common stock relative to vesting of restricted stock, net of 4,789, 5,249 and 9,904 shares forfeited for tax obligations in 2012, 2013 and 2014 respectively, shares		41,759
Issuance of common stock pursuant to stock option plans	146	1	145
Issuance of common stock pursuant to stock option plans,Shares	48,427	48,427
Stock-based compensation	1,202		1,202
Net income (loss)	-7,608			-7,608
Ending Balance at Dec. 31, 2013	21,377	111	166,735	-144,054	-1,415
Ending Balance, shares at Dec. 31, 2013		11,084,119
Issuance of common stock relative to vesting of restricted stock, net of 4,789, 5,249 and 9,904 shares forfeited for tax obligations in 2012, 2013 and 2014 respectively	-110	1	-111
Issuance of common stock relative to vesting of restricted stock, net of 4,789, 5,249 and 9,904 shares forfeited for tax obligations in 2012, 2013 and 2014 respectively, shares		75,530
Issuance of common stock for warrants exercised	3,726	4	3,722
Issuance of common stock for warrants exercised, shares		450,000
Issuance of stock for acquisitions	8,556	12	8,544
Issuance of stock for acquisitions, shares		1,200,000
Issuance of common stock pursuant to stock option plans	708	1	707
Issuance of common stock pursuant to stock option plans,Shares	162,528	162,528
Sale of common stock	28,214	28	28,186
Sale of common stock, shares		2,760,000
Stock-based compensation	1,318		1,318
Net income (loss)	-1,009			-1,009
Ending Balance at Dec. 31, 2014	$62,779	$157	$209,100	($145,063)	($1,415)
Ending Balance, shares at Dec. 31, 2014		15,732,177

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Shares forfeited for tax obligations	9,904	5,249	4,789
Common Stock [Member]
Shares forfeited for tax obligations	9,904	5,249	4,789
Additional Paid-in Capital [Member]
Shares forfeited for tax obligations	9,904	5,249	4,789

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flow from operating activities:
Net loss	($1,009)	($7,608)	($9,374)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Depreciation	1,256	706	891
Amortization	2,270	1,724	1,904
Bad debt provision	167	35
Loss on extinguishment of debt	903
Loss on disposal of assets		53	174
Loss (gain) from change in fair value of warrant liability	-1,835	2,448	539
Stock-based compensation expense	1,318	1,202	996
Amortization of debt discount and debt costs	1,246	856	1,012
Interest on settlement obligations	206	266	388
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	-840	-2,678	-976
Inventory	-323	228	-79
Prepaid and other assets	11	-126	469
Accounts payable	150	60	815
Accrued expenses	296	-609	-1,775
Deferred revenue	-612	2,010	812
Total adjustments	4,213	6,175	5,170
Net cash provided by (used for) operating activities	3,204	-1,433	-4,204
Cash flow from investing activities:
Additions to patents, technology and other	-50	-168	-70
Additions to property and equipment	-1,214	-539	-665
Acquisition of Radion Inc, and DermEbx	-3,482
Net cash used for investing activities	-4,746	-707	-735
Cash flow from financing activities:
Issuance of common stock for cash, net	28,214
Stock option exercises	708	146
Warrant exercise	1,575
Taxes paid related to restricted stock issuance	-110	-28	-14
Principal payments of capital lease obligations	-655	-46
Principal repayment of debt financing, net	-7,850
Proceeds from debt financing, net			14,325
Net cash provided by financing activities	21,882	72	14,311
Increase (decrease) in cash and equivalents	20,340	-2,068	9,372
Cash and equivalents, beginning of year	11,880	13,948	4,576
Cash and equivalents, end of year	32,220	11,880	13,948
Supplemental disclosure of cash flow information:
Interest paid	1,637	2,163	1,516
Taxes paid	157	78	55
Equipment purchased under capital lease		409
Non-cash items from investing and financing activities:
Settlement of warrant liability with purchase of common stock	2,151
Issuance of common stock related to acquisition of Radion, Inc and DermEbx	$8,556

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	-1	Summary of Significant Accounting Policies

	(a) Nature of Operations and Use of Estimates

	iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer.

	The Company has grown primarily through acquisitions to become a broad player in the oncology market. Its industry-leading solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, MRI and CT, and the Xoft eBx system which is an isotope-free cancer treatment platform technology. CAD is reimbursable in the U.S. under federal and most third-party insurance programs.

	The Company intends to continue the extension of its image analysis and clinical decision support solutions for mammography, MRI and CT imaging. iCAD believes that advances in digital imaging techniques should bolster its efforts to develop additional commercially viable CAD/advanced image analysis and workflow products. The Company’s belief is that early detection in combination with earlier targeted intervention will provide patients and care providers with the best tools available to achieve better clinical outcomes resulting in a market demand that will drive top line growth.

	The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts and, an operation, research, development, manufacturing and warehousing facility in San Jose, California.

	The Company operates in two segments, Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy products. The Company sells its products throughout the world through its direct sales organization as well as through various OEM partners, distributors and resellers. See Note 7 for segment, major customer and geographical information.

	The Company has reclassified on the statement of operations revenue for disposable applicators and supplies of to service and supplies revenue that was previously included in product revenue to conform to current period classification. The Company has reclassified on the statement of operations for the revenue for disposable applicators and supplies and other related expenses service and supplies cost of revenue that was previously included in cost of product revenue to conform to current period classification. The Company reclassified depreciation previously included in product and service cost of revenue to amortization and depreciation as a separate component of cost of revenue.

	The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities.

	(b) Principles of Consolidation

	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries; Xoft, Inc. and Xoft Solutions, LLC. All material inter-company transactions and balances have been eliminated in consolidation.

	(c) Cash and cash equivalents

	The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less, which are unrestricted as to withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage is $250,000 per depositor at each financial institution, and the Company’s non-interest bearing cash balances exceed federally insured limits. Interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2014 approximated $31.1 million.

	(d) Financial instruments

	Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, notes payable and warrants. Due to their short term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2014 and 2013, with the exception of warrants. The fair value of warrants is more fully described in Note 1(r).

	(e) Accounts Receivable and Allowance for Doubtful Accounts

	Accounts receivable are customer obligations due under normal trade terms. Credit limits are established through a process of reviewing the financial history and stability of each customer. The Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral.



	The Company’s policy is to maintain allowances for estimated losses from the inability of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its overall allowance for doubtful accounts. An amount would be written off against the allowance after all attempts to collect the receivable had failed. Based on the information available, the Company believes the allowance for doubtful accounts as of December 31, 2014 and 2013 is adequate.

	The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2014 (in thousands):



			2014				2013				2012
	Balance at beginning of period		$	73			$	48			$	54
	Additions charged to costs and expenses			167				35				—
	Reductions			(37	)			(10	)			(6	)

	Balance at end of period		$	203			$	73			$	48


	(f) Inventory

	Inventory is valued at the lower of cost or market value, with cost determined by the first-in, first-out method. The Company regularly reviews inventory quantities on hand and records an allowance for excess and/or obsolete inventory primarily based upon the estimated usage of its inventory as well as other factors. At December 31, 2014 and 2013 respectively inventories consisted of the following (in thousands):



			As of December 31,
			2014				2013
	Raw materials		$	955			$	581
	Work in process			54				38
	Finished Goods			1,205				1,272

	Inventory		$	2,214			$	1,891


(g) Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, whichever is shorter for leasehold improvements (see below).



		Estimated life
Equipment			3-5 years
Leasehold improvements			3-5 years
Furniture and fixtures			3-5 years
Marketing assets			3-5 years

(h) Long Lived Assets

Long-lived assets, other than goodwill, are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows from the use of these assets. When any such impairment exists, the related assets are written down to fair value. The Company did not record any impairment losses in the years ended December 31, 2014, 2013 or 2012.

Intangible assets subject to amortization consist primarily of patents, technology, customer relationships and trade names purchased in the Company’s previous acquisitions. These assets, which include assets from the acquisition of the assets of DermEbx and Radion and the acquisition of Xoft, Inc., are amortized on a straight-line basis consistent with the pattern of economic benefit over their estimated useful lives of 5 to 15 years. A summary of intangible assets for 2014 and 2013 are as follows (in thousands):



		2014				2013				Weighted
										average
										useful life
Gross Carrying Amount
Patents and licenses		$	767			$	737				5 years
Technology			25,639				24,909				10 years
Customer relationships			5,548				248				7 years
Tradename			288				248				10 years

Total amortizable intangible assets			32,242				26,142

Accumulated Amortization
Patents and licenses		$	517			$	471
Technology			13,076				11,589
Customer relationships			896				160
Tradename			249				248

Total accumulated amortization			14,738				12,468

Total amortizable intangible assets, net		$	17,504			$	13,674




Amortization expense related to intangible assets was approximately $2,270, $1,724 and $1,904 for the years ended December 31, 2014, 2013, and 2012, respectively. Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands):



For the years ended December 31:		Estimated
		amortization
		expense
2015		$	3,095
2016			2,462
2017			2,254
2018			1,934
2019			1,659
Thereafter			6,100

		$	17,504


(i) Goodwill

In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles—Goodwill and Other”, (“ASC 350-20”), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.

Factors the Company considers important, which could trigger an impairment of such asset, include the following:


	•		significant underperformance relative to historical or projected future operating results;


	•		significant changes in the manner or use of the assets or the strategy for the Company’s overall business;


	•		significant negative industry or economic trends;


	•		significant decline in the Company’s stock price for a sustained period; and


	•		a decline in the Company’s market capitalization below net book value.

In June 2013, the Company determined that it had two reporting units and two reportable segments based on the information provided to the Chief Operating Decision Maker (“CODM”). Goodwill was allocated to the reporting units based on the relative fair value of the reporting units as of June 2013.

The Company performed an annual impairment assessment at October 1, 2014 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value of each reporting unit exceeded the carry value by approximately 315% for the Detection reporting unit and 255% for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment.



The Company would record an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of our reporting unit. The Company makes assumptions about future cash

flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made.

The Company determined the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company used internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts.

In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public subsidiaries that could otherwise qualify as comparable, and the specific circumstances surrounding a market transaction (e.g., synergies between the parties, terms and conditions of the transaction, etc.) may be different or irrelevant with respect to the business.

The Company corroborated the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weight the methodologies appropriately.

A rollforward of goodwill activity by reportable segment is as follows:



		Detection				Therapy				Total
Accumulated Goodwill		$	—			$	—			$	47,937
Accumulated impairment			—				—				(26,828	)
Fair value allocation			7,663				13,446				—

Balance at December 31, 2013			7,663				13,446				21,109

Acquistion of DermEbx and Radion			—				6,154				6,154

Balance at December 31, 2014		$	7,663			$	19,600			$	27,263


(j) Revenue Recognition

The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement.

The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”) and ASC Update No. 2009-14, “Certain Arrangements That Contain Software Elements” (“ASU 2009-14”) and ASC 985-605, “Software” (“ASC 985-605”). Revenue for the sale of certain CAD products is recognized in accordance with ASC 840 “Leases” (“ASC 840”). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“BESP”). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment, however, these may vary depending upon the unique facts and circumstances related to each deliverable.



The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references.

If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process.

The Company has determined that iCAD’s digital, and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates the revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered.

Revenue from the certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement, and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed.

The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with 985-605-25-71.

Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes in service and supplies revenue the following: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company’s AxxentHub

software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance.

The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, “Services”. The Company provides for estimated warranty costs on original product warranties at the time of sale.

(k) Cost of Revenue

Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house product warranty repairs, amortization of acquired technology and medical device tax.

(l) Warranty Costs

The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including in the volume and cost of product returns during the warranty period. Warranty provisions and claims for the years ended December 31, 2014, 2013 and 2012, were as follows (in thousands):



		2014				2013				2012
Beginning accrual balance		$	25			$	36			$	89
Warranty provision			58				96				37
Usage			(69	)			(107	)			(90	)

Ending accrual balance		$	14			$	25			$	36


The warranty costs above include long-term warranty obligations of $5,000, $8,000 and $10,000 for the years ended December 31, 2014, 2013 and 2011, respectively.

(m) Engineering and Product Development Costs

Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials which are expensed as incurred.

(n) Advertising Costs

The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2014, 2013 and 2012 was approximately $882,000, $639,000 and $762,000 respectively.



(o) Net Loss per Common Share

The Company follows FASB ASC 260-10, “Earnings per Share”, which requires the presentation of both basic and diluted earnings per share on the face of the statements of operations. The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period and, if there are dilutive securities, diluted income per share is computed by including common stock equivalents which includes shares issuable upon the exercise of stock options, net of shares assumed to have been purchased with the proceeds, using the treasury stock method.

A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts):



		2014				2013				2012
Net loss available to common shareholders		$	(1,009	)		$	(7,608	)		$	(9,374	)

Basic shares used in the calculation of earnings per share			14,096				10,842				10,796
Effect of dilutive securities:
Stock options			—				—				—
Restricted stock			—				—				—

Diluted shares used in the calculation of earnings per share			14,096				10,842				10,796

Net loss per share :
Basic		$	(0.07	)		$	(0.70	)		$	(0.87	)
Diluted		$	(0.07	)		$	(0.70	)		$	(0.87	)

The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive:



		2014				2013				2012
Common stock options			1,417,887				1,334,955				1,434,945
Warrants			—				550,000				550,000
Restricted Stock			309,317				216,250				67,075

			1,727,204				2,101,205				2,052,020


Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not considered outstanding until vested.



(p) Income Taxes

The Company follows the liability method under ASC Topic 740, “Income Taxes”, (“ASC 740”). The primary objectives of accounting for taxes under ASC 740 are to (a) recognize the amount of tax payable for the current year and (b) recognize the amount of deferred tax liability or asset for the future tax consequences of events that have been reflected in the Company’s financial statements or tax returns. The Company has provided a full valuation allowance against its deferred tax assets at December 31, 2014 and 2013, as it is more likely than not that the deferred tax asset will not be realized. Any subsequent changes in the valuation allowance will be recorded through operations in the provision (benefit) for income taxes.

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740-10 also provides guidance on de-recognition, classification, interest and penalties, disclosure and transition.

(q) Stock-Based Compensation

The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company may grant to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows FASB ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), for all stock-based compensation. Under this application, the Company is required to record compensation expense over the vesting period for all awards granted.

The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, the risk free rate, expected dividend yield, and the number of options that will be forfeited prior to the completion of their vesting requirements. Fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations.

(r) Fair Value Measurements

The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:


	•		Level 1 - Quoted prices in active markets for identical assets or liabilities.
	•		Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•		Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The Company’s liabilities that are measured at fair value on a recurring basis relate to contingent consideration resulting from the acquisition of Xoft and the warrants issued in connection with the financing arrangement.

The money market funds are included in cash and cash equivalents in the accompanying balance sheet, and are considered a level 1 investment as they are valued at quoted market prices in active markets.

The fair value measurement for the contingent consideration liability is valued using Level 3 inputs. In connection with the acquisition of Xoft, the Company recorded a contingent consideration liability of $5.0 million based upon the estimated fair value of the additional earn-out potential for the sellers that is tied to cumulative net revenue of Xoft products from January 1, 2011 through December 31, 2013, payable January, 2014. As of December 31, 2013, the Company did not meet the cumulative net revenue criteria and accordingly the value of the contingent consideration was $0.0 million.

In connection with the financing as further described in Note 3 the Company issued 550,000 warrants to Deerfield in December 2011. On April 30, 2014, Deerfield exercised 450,000 warrants for an aggregate purchase price of $1,575,000, and the Company issued 450,000 shares of common stock, and cancelled the remaining 100,000 warrants issued to Deerfield, since these 100,000 warrants were exercisable only in the event the Company extended the last debt payment for an additional year. The warrant obligation was fully satisfied following that exercise. The liability for the warrants associated with the debt was valued using the binomial lattice-based valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. The warrant was valued at $2,151,000 as of April 30, 2014 immediately prior to exercise which included a gain of $699,000. Significant assumptions in valuing the warrant liability were as follows as of December 31, 2013 and April 30, 2014.



		April 30, 2014				December 31, 2013
Warrants
Exercise price		$	3.5			$	3.5
Volatility			40.8	%			56.2	%
Equivalent term (years)			0				4
Risk-free interest rate			0.1	%			1.3	%

The following table sets forth Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.



Fair value measurements using: (000’s) as of December 31, 2014
		Level 1				Level 2				Level 3				Total
Assets
Money market accounts		$	26,530			$	—			$	—			$	26,530

Total Assets		$	26,530			$	—			$	—			$	26,530

Liabilities
Warrants			—				—				—				—

Total Liabilities		$	—			$	—			$	—			$	—


Fair value measurements using: (000’s) as of December 31, 2013
		Level 1				Level 2				Level 3				Total
Assets
Money market accounts		$	7,572			$	—			$	—			$	7,572

Total Assets		$	7,572			$	—			$	—			$	7,572

Liabilities
Contingent Consideration		$	—			$	—			$	—			$	—
Warrants			—				—				3,986				3,986

Total Liabilities		$	—			$	—			$	3,986			$	3,986




The following table provides a summary of changes in the fair value of the warrants during the period are as follows (in thousands):



Warrants		Amount
Balance as of December 31, 2012		$	1,538
Loss from change in fair value of warrant			2,448

Balance as of December 31, 2013			3,986
Gain from change in fair value of warrant			(1,835	)
Warrant exercise			(2,151	)

Balance as of December 31, 2014		$	—


Items Measured at Fair Value on a Nonrecurring Basis

Certain assets, including our goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. We recorded an estimated impairment charge for goodwill of $26.8 million during the year ended December 31, 2011. We did not consider any assets to be impaired during the years ended December 31, 2014, 2013 or 2012.

(s) Recently Issued Accounting Standards

In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. The new standard requires the Company to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The adoption of ASU 2014-15 is not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” (“ASU 2014-09”), which amends ASC 605 “Revenue Recognition” and creates a new Topic 606 “Revenue from Contracts with Customers.” This update provides guidance on how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Upon initial application, the provisions of this update are required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. This update also expands the disclosure requirements surrounding revenue recorded from contracts with customers. This update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the effect of this update on its financial statements and have not yet determined the method of initial application that it will use.

Acquisition_of_the_assets_of_D

Acquisition of the assets of DermEbx and Radion	12 Months Ended
Acquisition of the assets of DermEbx and Radion	Dec. 31, 2014
Business Combinations [Abstract]
Acquisition of the assets of DermEbx and Radion	-2	Acquisition of the assets of DermEbx and Radion

	On July 15, 2014 (the “Closing Date”), the Company entered into two Asset Purchase Agreements, one with Radion, the other with DermEbx (the “Acquisition”). Pursuant to the Asset Purchase Agreement with DermEbx, the Company purchased substantially all of the assets of DermEbx, including all of DermEbx’s intellectual property and customer contracts. The Company paid to DermEbx the following consideration: (i) $1,600,000 in cash and (ii) the issuance to DermEbx of 600,000 restricted shares of the Company’s common stock, $0.01 par value per share. The Company held back $500,000 of the cash consideration for purposes of a purchase price adjustment based on the working capital of DermEbx, which adjustment is in the settlement process. The 600,000 restricted shares are subject to the following provisions; 25% shall be restricted from resale up until the date that is two trading days after the Company announces its fourth quarter 2014 earnings; 30% of the shares shall be restricted from resale for a period of twenty-four (24) months from the date of the agreement; and 30% of the shares shall be restricted from resale for a period of thirty-six (36) months from the date of the agreement. In addition the Company delivered the remaining 15%, or 90,000, of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of eighteen (18) months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by DermEbx under the DermEbx Asset Purchase Agreement.

	Pursuant to the terms of the Asset Purchase Agreement with Radion, the Company purchased substantially all of the assets of Radion, including all of Radion’s intellectual property and customer contracts. The Company paid to Radion the following consideration: (i) $2,382,000 in cash which included $182,000 payoff of an existing note payable and (ii) the issuance to Radion of 600,000 restricted shares of the Company’s common stock. The 600,000 restricted shares are subject to the following provisions; 25% shall be restricted from resale until the date that is two trading days after the Company announces its fourth quarter 2014 earnings; 30% of the shares shall restricted from resale for a period of twenty-four (24) months from the date of the agreement; and 30% of the shares shall be restricted from resale for a period of thirty-six (36) months from the date of the agreement. In addition the Company delivered the remaining 15% or 90,000 of the restricted shares to US Bank, N.A., as escrow agent, to be held in escrow for a period of eighteen (18) months pursuant to the terms of an escrow agreement. The 90,000 escrow shares will act as the source of payment for the indemnification of the Company by Radion under the Radion Asset Purchase Agreement.

	As a result of the acquisitions of the assets of DermEbx and Radion the Company now offers solutions that enable dermatologists and radiation oncologists to develop, launch and manage their eBx programs for the treatment of non-melanoma skin cancer, which we believe will provide opportunities to drive additional revenues in our Cancer Therapy segment. We do not anticipate significant synergies from this business; however we were able to consolidate the business operations of DermEbx and Radion in our San Jose, California facility.



	The amounts allocated to purchased and developed software, customer relationships, trade names, employee non-compete agreements and backlog were estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under these methods include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. Acquired intangible assets are being amortized over the estimated useful lives as set forth in the following table. The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets:



			Amount			Estimated Amortizable Life
	Current assets		$	3,457
	Property and equipment			2,625			3–7 Years
	Identifiable intangible assets			6,050			5–10 Years
	Goodwill			6,154
	Current liabilities			(4,316	)
	Long-term liabilities			(2,114	)

	Purchase price		$	11,856


	The goodwill of $6.2 million is deductible for income tax purposes.

	The Condensed Consolidated Financial statements include the operations of DermEbx and Radion from the Closing Date through December 31, 2014, which represents revenue of approximately $7.9 million in the statement of operations.



	The unaudited proforma operating results for the Company for the years ended December 30, 2014 and 2013, respectively assuming the acquisition of the assets of DermEbx and Radion occurred as of January 1, 2013 are as follows (in thousands except per share amounts):



			31-Dec
			2014			2013
	Revenue		$	48,145		$	35,639
	Income (loss) from operations			2,518			(5,402	)
	Net income (loss)			538			(11,376	)
	Basic net income (loss) per share		$	0.04		$	(1.05	)
	Diluted net income (loss) per share			0.04			(1.05	)
	Basic shares			14,096			10,842
	Diluted shares			15,097			10,842

Financing_Arrangements

Financing Arrangements	12 Months Ended
Financing Arrangements	Dec. 31, 2014
Debt Disclosure [Abstract]
Financing Arrangements	-3	Financing Arrangements

	In December, 2011, the Company entered into several agreements with entities affiliated with Deerfield Management, a healthcare investment fund (“Deerfield”), pursuant to which Deerfield agreed to provide $15 million in funding to the Company. The agreements consist of a Facility Agreement (the “Facility Agreement”), a Revenue Purchase Agreement (the “Revenue Purchase Agreement”) and the issuance of warrants to purchase up to 550,000 shares of the Company’s common stock at an exercise price of $3.50 (the “Warrants”). In accordance with the Facility Agreement, the Company is obligated to repay $15 million in three payments due as follows: $3.75 million due December 2014, $3.75 million due December 2015, and $7.5 million due December 2016, together with interest on the outstanding obligation at 5.75% per annum. On October 29, 2014, the Company paid $3.75 million that was due in December 2014 to Deerfield under the Facility Agreement. The original agreement also specified the Company could extend the final payment of $7.5 million to $3.75 million in December 2016 and $3.75 million in December 2017. In accordance with the Revenue Purchase Agreement, the Company was obligated to pay 4.25% of annual revenues up to $25 million, 2.75% of annual revenues from $25 million to $50 million during 2013 and 2014, and 2.25% of annual revenues during 2015, 2016 and 2017 (if the Facility Agreement was extended), and 1.0% of annual revenues in excess of $50 million.

	On April 30, 2014, the Company agreed to pay Deerfield $4.1 million to terminate the Revenue Purchase Agreement, which eliminated the ability to extend the last debt payment for an additional year and eliminated the payment obligation for 2017 under the Revenue Purchase Agreement. The Company recorded a loss of $0.9 million in connection with termination of the Revenue Purchase Agreement. In addition, Deerfield exercised their Warrants, for an aggregate purchase price of $1,575,000, and the Company issued 450,000 shares of common stock to Deerfield, pursuant to the terms of the Warrants. The Warrants to purchase an additional 100,000 shares of common stock were cancelled, since these Warrants were exercisable only in the event the Company extended the last debt payment for an additional year.



	The following amounts are included in the consolidated balance sheet as of December 31, 2014 and 2013, respectively related to the Facility and Revenue Purchase agreements:



			December 31, 2014			December 31, 2013
	Principal Amount of Facility Agreement		$	15,000		$	15,000
	Unamortized discount			(1,898	)		(3,116	)
	Principal repayment			(3,750	)		—

	Carrying amount of Facility Agreement			9,352			11,884

	Revenue Purchase Agreement			—			3,636

	Less current portion of Facility Agreement			(3,750	)		(3,750	)

	Notes payable long-term portion		$	5,602		$	11,770


	The following amounts are included in interest expense in our consolidated statement of operations for the years ended December 31, 2014 and 2013:



			December 31, 2014			December 31, 2013
	Cash interest expense		$	1,271		$	2,155
	Non-cash amortization of debt discount			1,053			674
	Amortization of debt costs			110			182
	Amortization of settlement obligations			206			266

	Total interest expense		$	2,640		$	3,277


	Cash interest expense represents the amount of interest expected to be paid in cash under the agreements, which represents the interest of 5.75% on the Facility Agreement and the cash payments on the Revenue Purchase Agreement that was terminated in April 2014. Non-cash amortization is the amortization of the discount on the Facility Agreement. The amortization of debt costs represents the costs incurred with the financing, which is primarily the facility fee and the finder’s fee which has been capitalized and is expensed using the effective interest method. The amortization of the settlement obligations represent the interest associated with the settlement agreements for both Zeiss and Hologic, Inc. (”Hologic”), see Note 8(f) to our Consolidated Financial Statements.

Accrued_Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	-4	Accrued Expenses

	Accrued expenses consist of the following at December 31, (in thousands):



			2014		2013
	Accrued salary and related expenses		$	2,518	$	2,020
	Accrued accounts payable			1,589		1,012
	Accrued professional fees			414		284
	Accrued short term settlement costs			698		221
	Other accrued expenses			287		216
	Deferred rent			48		46

			$	5,554	$	3,799

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	-5	Stockholders’ Equity

	(a) Stock Options

	The Company has five stock option or stock incentive plans, which are described as follows:

	The 2001 Stock Option Plan (the “2001 Plan”).

	The 2001 Plan was adopted by the Company’s stockholders in August 2001. The 2001 Plan provides for the granting of non-qualifying and incentive stock options to employees and other persons to purchase up to an aggregate of 240,000 shares of the Company’s common stock. The purchase price of each share for which an option is granted is determined by the Board of Directors or the Committee appointed by the Board of Directors provided that the purchase price of each share for which an incentive option is granted cannot be less than the fair market value of the Company’s common stock on the date of grant, except for options granted to 10% stockholders for whom the exercise price cannot be less than 110% of the market price. Incentive options granted to date under the 2001 Plan vest 100% over periods extending from six months to five years from the date of grant and expire no later than ten years after the date of grant, except for 10% holders whose options shall expire not later than five years after the date of grant. Non-qualifying options granted under the 2001 Plan are generally exercisable over a ten year period, vesting 1/3 each on the first, second, and third anniversaries of the date of grant. At December 31, 2014 there are no further options available for grant under this plan.

	The 2002 Stock Option Plan (the “2002 Plan”).

	The 2002 Plan was adopted by the Company’s stockholders in June 2002. The 2002 Plan provides for the granting of non-qualifying and incentive stock options to employees and other persons to purchase up to an aggregate of 100,000 shares of the Company’s common stock. The purchase price of each share for which an option is granted is determined by the Board of Directors or the Committee appointed by the Board of Directors provided that the purchase price of each share for which an incentive option is granted cannot be less than the fair market value of the Company’s common stock on the date of grant, except for options granted to 10% stockholders for whom the exercise price cannot be less than 110% of the market price. Incentive options granted to date under the 2002 Plan vest 100% over periods extending from six months to five years from the date of grant and expire no later than ten years after the date of grant, except for 10% holders whose options expire not later than five years after the date of grant. Non-qualifying options granted under the 2002 Plan are generally exercisable over a ten year period, vesting 1/3 each on the first, second, and third anniversaries of the date of grant. At December 31, 2014, there are no further options available for grant under the 2002 Plan.

	The 2004 Stock Incentive Plan (the “2004 Plan”).

	The 2004 Plan was adopted by the Company’s stockholders in June 2004. The 2004 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. The 2004 Plan provides for the granting of non-qualifying and incentive stock options to employees and other persons to purchase up to an aggregate of 200,000 shares of the Company’s common stock. The purchase price of each share for which an option is granted is determined by the Board of Directors or the Committee appointed by the Board of Directors provided that the purchase price of each share for which an option is granted cannot be less than the fair market value of the Company’s common stock on the date of grant, except for incentive options granted to 10% stockholders for whom the exercise price cannot be less than 110% of the market price. Incentive options granted under the 2004 Plan generally vest 100% over periods extending from the date of grant to five years from the date of grant and expire not later than ten years after the date of grant, except for 10% holders whose options expire not later than five years after the date of grant. Non-qualifying options granted under the 2004 Plan are generally exercisable over a ten year period, vesting 1/3 each on the first, second, and third anniversaries of the date of grant. At December 31, 2014, there are no further shares available for grant under the 2004 Plan.

	The 2005 Stock Incentive Plan (the “2005 Plan”).

	The 2005 Plan was adopted by the Company’s stockholders in June 2005. The 2005 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. The 2005 Plan provides for the granting of non-qualifying and incentive stock options to employees and other persons to purchase up to an aggregate of 120,000 shares of the Company’s common stock. The purchase price of each share for which an option is granted is determined by the Board of Directors or the Committee appointed by the Board of Directors provided that the purchase price of each share for which an option is granted cannot be less than the fair market value of the Company’s common stock on the date of grant, except for incentive options granted to 10% stockholders for whom the exercise price cannot be less than 110% of the market price. Incentive options granted under the 2005 Plan generally vest 100% over periods extending from the date of grant to three years from the date of grant and expire not later than five years after the date of grant, except for 10% stockholders whose options expire not later than five years after the date of grant. Non-qualifying options granted under the 2005 Plan are generally exercisable over a ten year period, vesting 1/3 each on the first, second, and third anniversaries of the date of grant. At December 31, 2014, there were 9,773 shares available for issuance under the 2005 Plan.



	The 2007 Stock Incentive Plan (the “2007 Plan”).

	The 2007 Plan was adopted by the Company’s stockholders in July 2007 and amended in June 2009. The 2007 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. Awards may be granted singly, in combination, or in tandem. Subject to anti-dilution adjustments as provided in the 2007 Plan, (i) the 2007 Plan provides for a total of 1,050,000 shares of the Company’s common stock to be available for distribution pursuant to the 2007 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options, restricted stock, deferred stock, or other stock-based awards may be granted to any participant under the 2007 Plan during any calendar year or part of a year may not exceed 160,000 shares.

	The 2007 Plan provides that it will be administered by the Company’s Board of Directors (“Board”) or a committee of two or more members of the Board appointed by the Board. The administrator will generally have the authority to administer the 2007 Plan, determine participants who will be granted awards under the 2007 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2007 Plan may be granted to employees, directors, consultants and advisors of the Company and its subsidiaries. However, only employees of the Company and its subsidiaries will be eligible to receive options that are designated as incentive stock options.

	With respect to options granted under the 2007 Plan, the exercise price must be at least 100% (110% in the case of an incentive stock option granted to a 10% stockholder) of the fair market value of the common stock subject to the award, determined as of the date of grant. Restricted stock awards are shares of common stock that are awarded subject to the satisfaction of the terms and conditions established by the administrator. In general, awards that do not require exercise may be made in exchange for such lawful consideration, including services, as determined by the administrator. At December 31, 2014, there were 28,854 shares available for issuance under the 2007 Plan.

	The 2012 Stock Incentive Plan (the “2012 Plan”).

	The 2012 Plan was adopted by the Company’s stockholders in May 2012 and amended in May 2014. The 2012 Plan, as amended, provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. Awards may be granted singly, in combination, or in tandem. Subject to anti-dilution adjustments as provided in the amended 2012 Plan, (i) the amended 2012 Plan provides for a total of 1,600,000 shares of the Company’s common stock to be available for distribution pursuant to the amended 2012 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options, restricted stock, deferred stock, or other stock-based awards may be granted to any participant under the amended 2012 Plan during any calendar year or part of a year may not exceed 250,000 shares.



	The 2012 Plan provides that it will be administered by the Company’s Board of Directors (“Board”) or a committee of two or more members of the Board appointed by the Board. The administrator will generally have the authority to administer the 2012 Plan, determine participants who will be granted awards under the 2012 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2012 Plan may be granted to employees, directors, consultants and advisors of the Company and its subsidiaries. However, only employees of the Company and its subsidiaries will be eligible to receive options that are designated as incentive stock options.

	With respect to options granted under the 2012 Plan, the exercise price must be at least 100% (110% in the case of an incentive stock option granted to a 10% stockholder) of the fair market value of the common stock subject to the award, determined as of the date of grant. Restricted stock awards are shares of common stock that are awarded subject to the satisfaction of the terms and conditions established by the administrator. In general, awards that do not require exercise may be made in exchange for such lawful consideration, including services, as determined by the administrator. At December 31, 2014, there were 627,721 shares available for issuance under the 2012 Plan.

	A summary of stock option activity for all stock option plans is as follows:



			Number of				Weighted Average			Weighted Average
			Shares				Exercise Price			Remaining
										Contractual Term
	Outstanding, January 1, 2012			1,080,722			$	9.75
	Granted			693,601			$	2.43
	Exercised			—			$	0
	Forfeited			(339,378	)		$	15.95

	Outstanding, December 31, 2012			1,434,945			$	4.75
	Granted			46,537			$	5.42
	Exercised			(48,427	)		$	3
	Forfeited			(98,100	)		$	11.62

	Outstanding, December 31, 2013			1,334,955			$	4.34
	Granted			281,043			$	8.08
	Exercised			(162,528	)		$	4.36
	Forfeited			(35,583	)		$	13.62

Outstanding, December 31, 2014			1,417,887			$	4.84			6.6 years

Exercisable at December 31, 2012			485,553			$	7.06

Exercisable at December 31, 2013			743,910			$	5.09

Exercisable at December 31, 2014			955,210			$	4.43			5.8 years


Available for future grants at December 31, 2014 from all plans: 666,348



The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands):



		Years Ended December 31,
		2014				2013			2012
Cost of revenue		$	13			$	21		$	15
Engineering and product development			165				228			178
Marketing and sales			353				273			242
General and administrative expense			787				680			561

		$	1,318			$	1,202		$	996


As of December 31, 2014, there was $2.2 million of total unrecognized compensation costs related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of 1.19 years.

Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values:



		Years Ended December 31,
		2014				2013			2012
Average risk-free interest rate			0.85%				0.53%			0.98%
Expected dividend yield			None				None			None
Expected life			3.5 years				3.5 years			3.5 years
Expected volatility			64.2% to 69.4%				57.6% to 68.9%			65.9% to 68.9%
Weighted average exercise price		$	8.09			$	5.42		$	2.43
Weighted average fair value		$	3.84			$	2.35		$	1.17

The Company’s 2014, 2013 and 2012, average expected volatility and average expected life is based on the average of the Company’s historical information. The risk-free rate is based on the rate of U.S. Treasury zero-coupon issues with a remaining term equal to the expected life of option grants. The Company has paid no dividends on its common stock in the past and does not anticipate paying any dividends in the future

The aggregate intrinsic value of options outstanding at December 31, 2014, 2013 and 2012 was $6.3 million, $10.0 million and $1.8 million, respectively. The aggregate intrinsic value of the options exercisable at December 31, 2014, 2013 and 2012 was $4.6 million, $5.1 million and $0.3 million, respectively. The aggregate intrinsic value of stock options exercised during 2014, 2013 and 2012 was $1.0 million, $0.5 million and $0, respectively. The Company used the closing market price of $9.17, $11.66 and $4.79 per share at December 31, 2014, 2013 and 2012, respectively, to determine the aggregate intrinsic values of options outstanding and exercisable.



(b) Restricted Stock

The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from grant date. A summary of restricted stock activity for all equity incentive plans is as follows:



		Years Ended December 31,
		2014				2013			2012
Beginning outstanding balance			216,250				67,075			122,795
Granted			180,500				196,250			—
Vested			(85,434	)			(47,008	)		(47,820	)
Forfeited			(1,999	)			(67	)		(7,900	)

Ending outstanding balance			309,317				216,250			67,075


The aggregate intrinsic value of restricted stock outstanding at December 31, 2014, 2013 and 2012 was $2.8 million, $2.5 million, and $0.3 million, respectively. The aggregate intrinsic value of restricted stock vested during 2014, 2013 and 2012 was $0.8 million, $0.5 million and $0.2 million, respectively. The Company used the closing market price of $9.17, $11.66 and $4.79 per share at December 31, 2014, 2013 and 2012, respectively, to determine the aggregate intrinsic values.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	-5	Income Taxes
	The components of income tax expense for the years ended December 31, 2014, 2013 and 2012 are as follows:


			2014			2013			2012
	Current provision (benefit):
	Federal		$	0		$	—		$	—
	State			126			43			76

			$	126		$	43		$	76

	A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31, 2014, 2013 and 2012 is as follows:


			2014			2013			2012
	Federal statutory rate			34	%		34	%		34	%
	State income taxes, net of federal benefit			5.5	%		2.3	%		4	%
	Net state impact of deferred rate change			13	%		0.1	%		0.1	%
	Stock compensation expense			(9.6	%)		(2.0	%)		(1.8	%)
	Tax amortization on goodwill			(9.0	%)		0	%		0	%
	Goodwill impairment			0	%		0	%		0	%
	Contingent consideration			0	%		0	%		0	%
	Loss on warrant			71.6	%		0	%		0	%
	Other permanent differences			(1.1	%)		(11.7	%)		(2.4	%)
	Change in valuation allowance			(222.6	%)		(27.6	%)		(34.4	%)
	Other			100.8	%		3.3	%		0	%

	Effective income tax			(17.4	%)		(1.6	%)		(0.5	%)

	Deferred tax assets and liabilities are recognized for the expected future tax consequences of net operating loss carryforwards, tax credit carryforwards and temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that the deferred tax assets will not be realized.

	Deferred income taxes reflect the impact of “temporary differences” between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. The Company has fully reserved the net deferred tax assets, as it is more likely than not that the deferred tax assets will not be utilized. Deferred tax assets (liabilities) are comprised of the following at December 31 (in thousands):


			2014			2013
	Inventory (Section 263A)		$	191		$	233
	Inventory reserves			106			156
	Receivable reserves			197			29
	Other accruals			887			938
	Deferred revenue			1,142			1,256
	Accumulated depreciation/amortization			(2,876	)		(2	)
	Stock options			2,252			2,070
	Developed technology			0			(3,464	)
	Tax credits			3,054			2,176
	NOL carryforward			34,690			34,059

	Net deferred tax assets			39,643			37,451
	Valuation allowance			(39,643	)		(37,451	)
	Goodwill tax amortization			(79	)		—

	Deferred tax liability		$	(79	)	$	—

	The increase in net deferred tax asset and corresponding valuation allowance is primarily attributable to additional research and development credits and differences in amortization periods on the Company’s intangible assets.
	As of December 31, 2014, the Company has net operating loss carryforwards totaling approximately $94.9 million expiring between 2016 and 2034. A portion of the total net operating loss carryforwards amounting to approximately $25.2 million relate to the acquisition of Xoft, Inc. As of December 31, 2014, the Company has provided a valuation allowance for its net operating loss carryforwards due to the uncertainty of the Company’s ability to generate sufficient taxable income in future years to obtain the benefit from the utilization of the net operating loss carryforwards. In the event of a deemed change in control, an annual limitation imposed on the utilization of the net operating losses may result in the expiration of all or a portion of the net operating loss carryforwards. There were no net operating losses utilized for the years ended December 31, 2014 and 2013.
	The Company currently has approximately $15.2 million (including approximately $9.5 million that relate to Xoft, Inc.) in net operating losses that are subject to limitations, of which approximately $2.0 million (including approximately $473,000 that relate to Xoft, Inc.) can be used annually through 2034. The Company has available tax credit carryforwards (adjusted to reflect provisions of the Tax Reform Act of 1986) to offset future income tax liabilities totaling approximately $2.2 million. The Company currently has approximately $3.9 million (including approximately $1.8 million that relate to Xoft, Inc.) in tax credit carryforwards that are subject to limitations. The tax credits related to Xoft have been fully reserved for and as a result no deferred tax asset has been recorded. The credits expire in various years through 2034.

	ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.
	As of December 31, 2014 and 2013, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC 740-10. The Company’s practice was and continues to be to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the years ended December 31, 2014, 2013 and 2012. The Company files United States federal and various state income tax returns. Generally, the Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. The Company completed an examination by the Internal Revenue Service with respect to the 2008 tax year in January 2011, which resulted in no changes to the tax return originally filed. The Company is not under examination by any other federal or state jurisdiction for any tax year.
	The Company does not anticipate that it is reasonably possible that unrecognized tax benefits as of December 31, 2014 will significantly change within the next 12 months.

Segment_Reporting_Geographical

Segment Reporting, Geographical Information and Major Customers	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting, Geographical Information and Major Customers	-7	Segment Reporting, Geographical Information and Major Customers

	(a) Segment Reporting

	In accordance with FASB Topic ASC 280, “Segments”, operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance.

	The Company’s CODM is the Chief Executive Officer (“CEO”). Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”).

	The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy (“Axxent”) products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring items (“Adjusted EBITDA”) of each segment. Included in segment operating income are stock compensation, amortization of technology and depreciation expense. There are no intersegment revenues.

	We do not track our assets by operating segment and our CODM does not use asset information by segment to allocate resources or make operating decisions.



	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands, including prior periods which have been presented for consistency):



			Year Ended December 31,
			2014			2013			2012
	Segment revenues:
	Detection		$	18,604		$	16,905		$	17,262
	Therapy			25,320			16,162			11,013

	Total Revenue		$	43,924		$	33,067		$	28,275

	Segment gross profit:
	Detection		$	15,276		$	13,576		$	13,936
	Therapy			15,951			9,509			6,095

	Segment gross profit		$	31,227		$	23,085		$	20,031

	Segment operating income (loss):
	Detection		$	7,231		$	5,016		$	4,274
	Therapy			1,868			(52	)		(2,720	)

	Segment operating income		$	9,099		$	4,964		$	1,554

	General, administrative, depreciation and amortization expense		$	(8,284	)	$	(6,740	)	$	(6,966	)
	Interest expense			(2,640	)		(3,277	)		(3,415	)
	Gain on fair value of warrant			1,835			(2,448	)		(539	)
	Other income			37			19			35
	Loss on debt extinguishment			(903	)		—			—

	Loss before income tax		$	(856	)	$	(7,482	)	$	(9,331	)


	Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands):



	Detection depreciation and amortization
	Depreciation			188			175			144
	Amortization			515			517			519
	Therapy depreciation and amortization
	Depreciation			844			424			595
	Amortization			1,739			939			931

	(b) Geographic Information

	The Company’s sales are made to customers, distributors and dealers of mammography, electronic brachytherapy equipment and other medical equipment, and to foreign distributors of mammography and electronic brachytherapy equipment. Export sales to a single country did not exceed 10% of total revenue in any year. Total export sales were approximately $1.8 million or 4% of total revenue in 2014, $1.9 million or 6% of total revenue in 2013 and $2.9 million or 10% of total revenue in 2012.



As of December 31, 2014 and 2013, the Company had outstanding receivables of $0.3 million from distributors and customers of its products who are located outside of the U.S.

(c) Major Customers

The Company had one major customer, GE Healthcare, with approximately $4.1 million in 2014, $3.7 million in 2013, and $4.5 million in 2012 or 9.4%, 11%, and 16% of total revenue, respectively. Cancer detection products are also sold through OEM partners, including GE Healthcare, Fuji Medical Systems, Siemens Medical and Invivo. These four OEM partners composed approximately 53% of Detection revenues and 22% of revenue overall.

OEM partners represented $1.9 million or 22% of outstanding receivables as of December 31, 2014, with GE Healthcare accounting for $1.3 million or 15% of this amount. The two largest Cancer Therapy customers composed $0.9 million or 10% of outstanding receivables as of December 31, 2014. These six customers in total represented $2.9 million or 33% of outstanding receivables as of December 31, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies

	(a) Lease Obligations

	As of December 31, 2014, the Company had three lease obligations related to its facilities. The Company’s executive offices are located in Nashua, New Hampshire and are leased pursuant to a five-year lease (the “Lease”) that commenced on December 15, 2006, and renewed on January 1, 2012 (the “Premises”). The Lease renewal provided for annual base rent of $181,764 for the first year; $187,272 for the second year; $192,780 for the third year; $198,288 for the fourth year and $203,796 for the fifth year. Additionally, the Company is required to pay its proportionate share of the building and real estate tax expenses and obtain insurance for the Premises. The Company also has the right to extend the term of the Lease for an additional five year period at the then current market rent rate (but not less than the last annual rent paid by the Company).

	The Company leases a facility in San Jose California under a non-cancelable operating lease which commenced in September, 2012. The facility has approximately 24,250 square feet of office, manufacturing and warehousing space. The operating lease provides for an annual base rent of $248,376, increasing to $260,064 in October 2013, $271,752 beginning October 2014, $283,440 beginning October 2015 and $295,140 beginning October 2016 through September 2017, with all amounts payable in equal monthly installments, with the right to extend the lease for an additional 3 year period. Additionally, the Company is required to pay its proportionate share of the building and real estate tax expenses and obtain insurance for the facility.



	In addition to the foregoing leases relating to its principal properties, the Company also has a lease for an additional facility in Nashua, New Hampshire used for product repairs, manufacturing and warehousing.

	Rent expense for all leases for the years ended December 31, 2014, 2013 and 2012 was $643,000, $697,000 and $799,000, respectively.

	Future minimum rental payments due under these agreements as of December 31, 2014 are as follows (in thousands):



	Fiscal Year	Operating
		Leases
	2015		482
	2016		490
	2017		255

		$	1,227


	(b) Capital leases obligations

	The Company entered into a capital lease agreement for the purchase of certain equipment in August 2013 for approximately $409,000 at a rate of 3.99%. Under the guidance of ASC Topic 840, “Leases” the Company determined that the lease was a capital lease as it contained a bargain purchase option wherein the Company has the option to buy the equipment for $1 at the end of the lease term. Accordingly, the equipment has been capitalized and a liability has been recorded. The equipment cost of $409,000 is reflected as property and equipment in the balance sheet and will be depreciated over its useful life. As of December 31, 2014, the remaining obligation is $0.2 million.

	In connection with the Acquisition, the Company assumed two separate equipment lease obligations with payments totaling approximately $2.6 million through May, 2017. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $2.5 million was recorded. As of December 31, 2014, the outstanding liability for the acquired equipment leases was approximately $2.1 million.



	Future minimum lease payments under all outstanding capital leases are as follows: (in thousands)

	Future minimum lease payments under this lease are as follows:



	Fiscal Year	Capital Leases
	2015		1,513
	2016		1,004
	2017		89

	subtotal minimum lease obligation		2,606
	less interest		(292	)

	Total, net		2,314
	less current portion		(1,294	)

	long term portion	$	1,020


	(c) Other Commitments

	The Company has non-cancelable purchase orders with three key suppliers executed in the normal course of business that total approximately $1.0 million. In connection with our employee savings plans, our matching contribution for 2014 was approximately $0.4 million in cash. Our matching contribution for 2015 is estimated to be approximately $0.5 million in cash.

	(d) Employment Agreements

	The Company has entered into employment agreements with certain key executives. The employment agreements provide for minimum annual salaries and performance-based annual bonus compensation as defined in their respective agreements. In addition, the employment agreements provide that if employment is terminated without cause, the executive will receive an amount equal to their respective base salary then in effect for the greater of the remainder of the original term of employment or, for Mr. Ferry, a period of two years from the date of termination, for Mr. Burns, a period of eighteen months from the date of termination and for all other executives a period of one year from the date of termination, in each case, plus the pro rata portion of any annual bonus earned in any employment year through the date of termination.

	(e) Foreign Tax Claim

In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment of approximately $6,800,000 from the Canada Revenue Agency (“CRA”) resulting from CRA’s audit of CADx Medical’s Canadian federal tax return for the year ended December 31, 2002. In February 2010, the CRA reviewed the matter and reduced the tax re-assessment to approximately $703,000, excluding interest and penalties. The CRA has the right to pursue the matter until July 2017. The Company believes that it is not liable for the re-assessment against CADx Medical and continues to defend this position. As the Company believes that a probability of a loss is remote, no accrual was recorded as of December 31, 2014.



(f) Royalty Obligations

In connection with prior litigation, the Company received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete covenant as well as an agreement not to seek further damages with respect to the alleged patent violations. In return the Company has a remaining obligation to pay a minimum annual royalty payment of $250,000 payable through 2016. In addition to the minimum annual royalty payments, the litigation settlement agreement with Hologic also provided for payment of royalties if such royalties exceed the minimum payment based upon a specified percentage of future net sales on any products that practice the licensed rights. The estimated fair value of the patent license and non-compete covenant is $100,000 and is being amortized over the estimated remaining useful life of approximately four years. In addition, a liability has been recorded within accrued expenses and long-term settlement cost for future payment and for future minimum royalty obligations totaling $0.6 million

During December, 2011, the Company settled litigation with Zeiss and as of December 31, 2014 has a remaining obligation to pay $0.5 million in June 2015 and $0.5 million in June 2017, for a total of $1.0 million. The present value of the liability is estimated at approximately $0.8 million as of December 31, 2014.

(g) Litigation

The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should we fail to prevail in any legal matter or should several legal matters be resolved against us in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Quarterly_Financial_Data

Quarterly Financial Data	12 Months Ended
Quarterly Financial Data	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	(9) Quarterly Financial Data (unaudited in thousands, except per share data)



		Net		Gross		Net			Income (loss)			Weighted
		sales		profit		income (loss)			per share			average
												number of
												shares outstanding
	2014
	First quarter	$	8,520	$	5,934	$	(190	)	($	0.02	)		11,429
	Second quarter		9,667		6,830	$	(997	)	($	0.07	)		14,074
	Third quarter		12,572		9,167	$	274		$	0.02			15,283
	Fourth quarter		13,165		9,296	$	(96	)	($	0.01	)		15,541
	2013
	First quarter	$	7,930	$	5,648	$	(727	)	($	0.07	)		10,820
	Second quarter		7,712		5,222	$	(1,882	)	($	0.17	)		10,836
	Third quarter		8,290		5,926	$	(589	)	($	0.05	)		10,849
	Fourth quarter		9,135		6,289	$	(4,410	)	($	0.41	)		10,863

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Operations and Use of Estimates	(a) Nature of Operations and Use of Estimates

	iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer.

	The Company has grown primarily through acquisitions to become a broad player in the oncology market. Its industry-leading solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, MRI and CT, and the Xoft eBx system which is an isotope-free cancer treatment platform technology. CAD is reimbursable in the U.S. under federal and most third-party insurance programs.

	The Company intends to continue the extension of its image analysis and clinical decision support solutions for mammography, MRI and CT imaging. iCAD believes that advances in digital imaging techniques should bolster its efforts to develop additional commercially viable CAD/advanced image analysis and workflow products. The Company’s belief is that early detection in combination with earlier targeted intervention will provide patients and care providers with the best tools available to achieve better clinical outcomes resulting in a market demand that will drive top line growth.

	The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts and, an operation, research, development, manufacturing and warehousing facility in San Jose, California.

	The Company operates in two segments, Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy products. The Company sells its products throughout the world through its direct sales organization as well as through various OEM partners, distributors and resellers. See Note 7 for segment, major customer and geographical information.

	The Company has reclassified on the statement of operations revenue for disposable applicators and supplies of to service and supplies revenue that was previously included in product revenue to conform to current period classification. The Company has reclassified on the statement of operations for the revenue for disposable applicators and supplies and other related expenses service and supplies cost of revenue that was previously included in cost of product revenue to conform to current period classification. The Company reclassified depreciation previously included in product and service cost of revenue to amortization and depreciation as a separate component of cost of revenue.

	The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities.
Principles of Consolidation	(b) Principles of Consolidation

	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries; Xoft, Inc. and Xoft Solutions, LLC. All material inter-company transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents	(c) Cash and cash equivalents

	The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less, which are unrestricted as to withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage is $250,000 per depositor at each financial institution, and the Company’s non-interest bearing cash balances exceed federally insured limits. Interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2014 approximated $31.1 million.
Financial Instruments	(d) Financial instruments
Financial Instruments	Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, notes payable and warrants. Due to their short term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2014 and 2013, with the exception of warrants. The fair value of warrants is more fully described in Note 1(r).
Accounts Receivable and Allowance for Doubtful Accounts	(e) Accounts Receivable and Allowance for Doubtful Accounts

	Accounts receivable are customer obligations due under normal trade terms. Credit limits are established through a process of reviewing the financial history and stability of each customer. The Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral.



	The Company’s policy is to maintain allowances for estimated losses from the inability of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its overall allowance for doubtful accounts. An amount would be written off against the allowance after all attempts to collect the receivable had failed. Based on the information available, the Company believes the allowance for doubtful accounts as of December 31, 2014 and 2013 is adequate.

	The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2014 (in thousands):



			2014			2013			2012
	Balance at beginning of period		$	73		$	48		$	54
	Additions charged to costs and expenses			167			35			—
	Reductions			(37	)		(10	)		(6	)

	Balance at end of period		$	203		$	73		$	48

Inventory	(f) Inventory
	Inventory is valued at the lower of cost or market value, with cost determined by the first-in, first-out method. The Company regularly reviews inventory quantities on hand and records an allowance for excess and/or obsolete inventory primarily based upon the estimated usage of its inventory as well as other factors. At December 31, 2014 and 2013 respectively inventories consisted of the following (in thousands):


			As of December 31,
			2014			2013
	Raw materials		$	955		$	581
	Work in process			54			38
	Finished Goods			1,205			1,272

	Inventory		$	2,214		$	1,891

Property and Equipment	(g) Property and Equipment

	Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, whichever is shorter for leasehold improvements (see below).



			Estimated life
	Equipment			3-5 years
	Leasehold improvements			3-5 years
	Furniture and fixtures			3-5 years
	Marketing assets			3-5 years
Long Lived Assets	(h) Long Lived Assets

	Long-lived assets, other than goodwill, are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows from the use of these assets. When any such impairment exists, the related assets are written down to fair value. The Company did not record any impairment losses in the years ended December 31, 2014, 2013 or 2012.

	Intangible assets subject to amortization consist primarily of patents, technology, customer relationships and trade names purchased in the Company’s previous acquisitions. These assets, which include assets from the acquisition of the assets of DermEbx and Radion and the acquisition of Xoft, Inc., are amortized on a straight-line basis consistent with the pattern of economic benefit over their estimated useful lives of 5 to 15 years. A summary of intangible assets for 2014 and 2013 are as follows (in thousands):



			2014			2013			Weighted
									average
									useful life
	Gross Carrying Amount
	Patents and licenses		$	767		$	737			5 years
	Technology			25,639			24,909			10 years
	Customer relationships			5,548			248			7 years
	Tradename			288			248			10 years

	Total amortizable intangible assets			32,242			26,142

	Accumulated Amortization
	Patents and licenses		$	517		$	471
	Technology			13,076			11,589
	Customer relationships			896			160
	Tradename			249			248

	Total accumulated amortization			14,738			12,468

	Total amortizable intangible assets, net		$	17,504		$	13,674




	Amortization expense related to intangible assets was approximately $2,270, $1,724 and $1,904 for the years ended December 31, 2014, 2013, and 2012, respectively. Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands):



	For the years ended December 31:		Estimated
			amortization
			expense
	2015		$	3,095
	2016			2,462
	2017			2,254
	2018			1,934
	2019			1,659
	Thereafter			6,100

			$	17,504

Goodwill	(i) Goodwill

	In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles—Goodwill and Other”, (“ASC 350-20”), the Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the Company is less than the carrying value of the Company.

	Factors the Company considers important, which could trigger an impairment of such asset, include the following:


		•		significant underperformance relative to historical or projected future operating results;


		•		significant changes in the manner or use of the assets or the strategy for the Company’s overall business;


		•		significant negative industry or economic trends;


		•		significant decline in the Company’s stock price for a sustained period; and


		•		a decline in the Company’s market capitalization below net book value.

	In June 2013, the Company determined that it had two reporting units and two reportable segments based on the information provided to the Chief Operating Decision Maker (“CODM”). Goodwill was allocated to the reporting units based on the relative fair value of the reporting units as of June 2013.

	The Company performed an annual impairment assessment at October 1, 2014 and compared the fair value of each of reporting unit to its carrying value as of this date. Fair value of each reporting unit exceeded the carry value by approximately 315% for the Detection reporting unit and 255% for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment.



	The Company would record an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of our reporting unit. The Company makes assumptions about future cash

	flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made.

	The Company determined the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company used internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts.

	In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public subsidiaries that could otherwise qualify as comparable, and the specific circumstances surrounding a market transaction (e.g., synergies between the parties, terms and conditions of the transaction, etc.) may be different or irrelevant with respect to the business.

	The Company corroborated the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weight the methodologies appropriately.

	A rollforward of goodwill activity by reportable segment is as follows:



			Detection			Therapy			Total
	Accumulated Goodwill		$	—		$	—		$	47,937
	Accumulated impairment			—			—			(26,828	)
	Fair value allocation			7,663			13,446			—

	Balance at December 31, 2013			7,663			13,446			21,109

	Acquistion of DermEbx and Radion			—			6,154			6,154

	Balance at December 31, 2014		$	7,663		$	19,600		$	27,263

Revenue Recognition	(j) Revenue Recognition

	The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement.

	The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, “Multiple-Deliverable Revenue Arrangements” (“ASU 2009-13”) and ASC Update No. 2009-14, “Certain Arrangements That Contain Software Elements” (“ASU 2009-14”) and ASC 985-605, “Software” (“ASC 985-605”). Revenue for the sale of certain CAD products is recognized in accordance with ASC 840 “Leases” (“ASC 840”). For multiple element arrangements, revenue is allocated to all deliverables based on their relative selling prices. In such circumstances, a hierarchy is used to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“BESP”). VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. The process for determining BESP for deliverables without VSOE or TPE considers multiple factors including relative selling prices; competitive prices in the marketplace, and management judgment, however, these may vary depending upon the unique facts and circumstances related to each deliverable.



	The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references.

	If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process.

	The Company has determined that iCAD’s digital, and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. Typically, the responsibility for the installation process lies with the OEM partner. On occasion, when iCAD is responsible for product installation, the installation element is considered a separate unit of accounting because the delivered product has stand-alone value to the customer. In these instances, the Company allocates the revenue to the deliverables based on the framework established within ASU 2009-13. Therefore, the installation and training revenue is recognized as the services are performed according to the BESP of the element. Revenue from the digital and film based equipment when there is installation, is recognized based on the relative selling price allocation of the BESP, when delivered.

	Revenue from the certain CAD products is recognized in accordance with ASC 985-605. Sales of this product include training, and the Company has established VSOE for this element. Product revenue is determined based on the residual value in the arrangement, and is recognized when delivered. Revenue for training is deferred and recognized when the training has been completed.

	The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with 985-605-25-71.

	Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. Product revenue is generally recognized when the product has been delivered and service and source revenue is typically recognized over the life of the service and source agreement. The Company includes in service and supplies revenue the following: the sale of physics and management services, the lease of electronic brachytherapy equipment, development fees, supplies and the right to use the Company’s AxxentHub

	software. Physics and management services revenue and development fees are considered to be delivered as the services are performed or over the estimated life of the agreement. The Company typically bills items monthly over the life of the agreement except for development fees, which are generally billed in advance or over a 12 month period and the fee for treatment supplies which is generally billed in advance.

	The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, “Services”. The Company provides for estimated warranty costs on original product warranties at the time of sale.
Cost of Revenue	(k) Cost of Revenue

	Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house product warranty repairs, amortization of acquired technology and medical device tax.
Warranty Costs	(l) Warranty Costs

	The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including in the volume and cost of product returns during the warranty period. Warranty provisions and claims for the years ended December 31, 2014, 2013 and 2012, were as follows (in thousands):



			2014			2013			2012
	Beginning accrual balance		$	25		$	36		$	89
	Warranty provision			58			96			37
	Usage			(69	)		(107	)		(90	)

	Ending accrual balance		$	14		$	25		$	36


	The warranty costs above include long-term warranty obligations of $5,000, $8,000 and $10,000 for the years ended December 31, 2014, 2013 and 2011, respectively.
Engineering and Product Development Costs	(m) Engineering and Product Development Costs
Engineering and Product Development Costs	Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials which are expensed as incurred.
Advertising Costs	(n) Advertising Costs
Advertising Costs	The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2014, 2013 and 2012 was approximately $882,000, $639,000 and $762,000 respectively.
Net Loss per Common Share	(o) Net Loss per Common Share

	The Company follows FASB ASC 260-10, “Earnings per Share”, which requires the presentation of both basic and diluted earnings per share on the face of the statements of operations. The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period and, if there are dilutive securities, diluted income per share is computed by including common stock equivalents which includes shares issuable upon the exercise of stock options, net of shares assumed to have been purchased with the proceeds, using the treasury stock method.

	A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts):



			2014			2013			2012
	Net loss available to common shareholders		$	(1,009	)	$	(7,608	)	$	(9,374	)

	Basic shares used in the calculation of earnings per share			14,096			10,842			10,796
	Effect of dilutive securities:
	Stock options			—			—			—
	Restricted stock			—			—			—

	Diluted shares used in the calculation of earnings per share			14,096			10,842			10,796

	Net loss per share :
	Basic		$	(0.07	)	$	(0.70	)	$	(0.87	)
	Diluted		$	(0.07	)	$	(0.70	)	$	(0.87	)

	The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive:



			2014			2013			2012
	Common stock options			1,417,887			1,334,955			1,434,945
	Warrants			—			550,000			550,000
	Restricted Stock			309,317			216,250			67,075

				1,727,204			2,101,205			2,052,020


	Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not considered outstanding until vested.
Income Taxes	(p) Income Taxes
	The Company follows the liability method under ASC Topic 740, “Income Taxes”, (“ASC 740”). The primary objectives of accounting for taxes under ASC 740 are to (a) recognize the amount of tax payable for the current year and (b) recognize the amount of deferred tax liability or asset for the future tax consequences of events that have been reflected in the Company’s financial statements or tax returns. The Company has provided a full valuation allowance against its deferred tax assets at December 31, 2014 and 2013, as it is more likely than not that the deferred tax asset will not be realized. Any subsequent changes in the valuation allowance will be recorded through operations in the provision (benefit) for income taxes.
	ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740-10 also provides guidance on de-recognition, classification, interest and penalties, disclosure and transition.
Stock-Based Compensation	(q) Stock-Based Compensation

	The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company may grant to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows FASB ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), for all stock-based compensation. Under this application, the Company is required to record compensation expense over the vesting period for all awards granted.

	The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, the risk free rate, expected dividend yield, and the number of options that will be forfeited prior to the completion of their vesting requirements. Fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations.
Fair Value Measurements	(r) Fair Value Measurements

	The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:


		•		Level 1 - Quoted prices in active markets for identical assets or liabilities.
		•		Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value

	A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

	The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The Company’s liabilities that are measured at fair value on a recurring basis relate to contingent consideration resulting from the acquisition of Xoft and the warrants issued in connection with the financing arrangement.

	The money market funds are included in cash and cash equivalents in the accompanying balance sheet, and are considered a level 1 investment as they are valued at quoted market prices in active markets.

	The fair value measurement for the contingent consideration liability is valued using Level 3 inputs. In connection with the acquisition of Xoft, the Company recorded a contingent consideration liability of $5.0 million based upon the estimated fair value of the additional earn-out potential for the sellers that is tied to cumulative net revenue of Xoft products from January 1, 2011 through December 31, 2013, payable January, 2014. As of December 31, 2013, the Company did not meet the cumulative net revenue criteria and accordingly the value of the contingent consideration was $0.0 million.

	In connection with the financing as further described in Note 3 the Company issued 550,000 warrants to Deerfield in December 2011. On April 30, 2014, Deerfield exercised 450,000 warrants for an aggregate purchase price of $1,575,000, and the Company issued 450,000 shares of common stock, and cancelled the remaining 100,000 warrants issued to Deerfield, since these 100,000 warrants were exercisable only in the event the Company extended the last debt payment for an additional year. The warrant obligation was fully satisfied following that exercise. The liability for the warrants associated with the debt was valued using the binomial lattice-based valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. The warrant was valued at $2,151,000 as of April 30, 2014 immediately prior to exercise which included a gain of $699,000. Significant assumptions in valuing the warrant liability were as follows as of December 31, 2013 and April 30, 2014.



			April 30, 2014			December 31, 2013
	Warrants
	Exercise price		$	3.5		$	3.5
	Volatility			40.8	%		56.2	%
	Equivalent term (years)			0			4
	Risk-free interest rate			0.1	%		1.3	%

	The following table sets forth Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.



	Fair value measurements using: (000’s) as of December 31, 2014
			Level 1			Level 2			Level 3			Total
	Assets
	Money market accounts		$	26,530		$	—		$	—		$	26,530

	Total Assets		$	26,530		$	—		$	—		$	26,530

	Liabilities
	Warrants			—			—			—			—

	Total Liabilities		$	—		$	—		$	—		$	—


	Fair value measurements using: (000’s) as of December 31, 2013
			Level 1			Level 2			Level 3			Total
	Assets
	Money market accounts		$	7,572		$	—		$	—		$	7,572

	Total Assets		$	7,572		$	—		$	—		$	7,572

	Liabilities
	Contingent Consideration		$	—		$	—		$	—		$	—
	Warrants			—			—			3,986			3,986

	Total Liabilities		$	—		$	—		$	3,986		$	3,986




	The following table provides a summary of changes in the fair value of the warrants during the period are as follows (in thousands):



Warrants		Amount
Balance as of December 31, 2012		$	1,538
Loss from change in fair value of warrant			2,448

Balance as of December 31, 2013			3,986
Gain from change in fair value of warrant			(1,835	)
Warrant exercise			(2,151	)

Balance as of December 31, 2014		$	—


Items Measured at Fair Value on a Nonrecurring Basis

Certain assets, including our goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. We recorded an estimated impairment charge for goodwill of $26.8 million during the year ended December 31, 2011. We did not consider any assets to be impaired during the years ended December 31, 2014, 2013 or 2012.
Segment Reporting	(a) Segment Reporting

	In accordance with FASB Topic ASC 280, “Segments”, operating segments, are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance.
Leases	Under the guidance of ASC Topic 840, “Leases” the Company determined that the lease was a capital lease as it contained a bargain purchase option wherein the Company has the option to buy the equipment for $1 at the end of the lease term. Accordingly, the equipment has been capitalized and a liability has been recorded.
Litigation	(g) Litigation

	The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should we fail to prevail in any legal matter or should several legal matters be resolved against us in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts	The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2014 (in thousands):



		2014			2013			2012
	Balance at beginning of period	$	73		$	48		$	54
	Additions charged to costs and expenses		167			35			—
	Reductions		(37	)		(10	)		(6	)

	Balance at end of period	$	203		$	73		$	48

Schedule of Current Inventory	At December 31, 2014 and 2013 respectively inventories consisted of the following (in thousands):


		As of December 31,
		2014			2013
	Raw materials	$	955		$	581
	Work in process		54			38
	Finished Goods		1,205			1,272

	Inventory	$	2,214		$	1,891

Schedule of Property and Equipment Estimated Useful Lives	Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, whichever is shorter for leasehold improvements (see below).



		Estimated life
	Equipment		3-5 years
	Leasehold improvements		3-5 years
	Furniture and fixtures		3-5 years
	Marketing assets		3-5 years
Schedule of Intangible Assets	A summary of intangible assets for 2014 and 2013 are as follows (in thousands):



		2014			2013			Weighted
								average
								useful life
	Gross Carrying Amount
	Patents and licenses	$	767		$	737			5 years
	Technology		25,639			24,909			10 years
	Customer relationships		5,548			248			7 years
	Tradename		288			248			10 years

	Total amortizable intangible assets		32,242			26,142

	Accumulated Amortization
	Patents and licenses	$	517		$	471
	Technology		13,076			11,589
	Customer relationships		896			160
	Tradename		249			248

	Total accumulated amortization		14,738			12,468

	Total amortizable intangible assets, net	$	17,504		$	13,674

Schedule of Expected Amortization Expense	Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands):



	For the years ended December 31:	Estimated
		amortization
		expense
	2015	$	3,095
	2016		2,462
	2017		2,254
	2018		1,934
	2019		1,659
	Thereafter		6,100

		$	17,504

Rollforward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment is as follows:



		Detection			Therapy			Total
	Accumulated Goodwill	$	—		$	—		$	47,937
	Accumulated impairment		—			—			(26,828	)
	Fair value allocation		7,663			13,446			—

	Balance at December 31, 2013		7,663			13,446			21,109

	Acquistion of DermEbx and Radion		—			6,154			6,154

	Balance at December 31, 2014	$	7,663		$	19,600		$	27,263

Roll forward of Warranty Cost	Warranty provisions and claims for the years ended December 31, 2014, 2013 and 2012, were as follows (in thousands):



		2014			2013			2012
	Beginning accrual balance	$	25		$	36		$	89
	Warranty provision		58			96			37
	Usage		(69	)		(107	)		(90	)

	Ending accrual balance	$	14		$	25		$	36

Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts):



		2014			2013			2012
	Net loss available to common shareholders	$	(1,009	)	$	(7,608	)	$	(9,374	)

	Basic shares used in the calculation of earnings per share		14,096			10,842			10,796
	Effect of dilutive securities:
	Stock options		—			—			—
	Restricted stock		—			—			—

	Diluted shares used in the calculation of earnings per share		14,096			10,842			10,796

	Net loss per share :
	Basic	$	(0.07	)	$	(0.70	)	$	(0.87	)
	Diluted	$	(0.07	)	$	(0.70	)	$	(0.87	)
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive:



		2014			2013			2012
	Common stock options		1,417,887			1,334,955			1,434,945
	Warrants		—			550,000			550,000
	Restricted Stock		309,317			216,250			67,075

			1,727,204			2,101,205			2,052,020

Schedule of Fair Value of Warrants	Significant assumptions in valuing the Warrant liability were as follows as of December 31, 2013 and April 30, 2014.


		April 30, 2014			December 31, 2013
	Warrants
	Exercise price	$	3.5		$	3.5
	Volatility		40.8	%		56.2	%
	Equivalent term (years)		0			4
	Risk-free interest rate		0.1	%		1.3	%
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.



	Fair value measurements using: (000’s) as of December 31, 2014
		Level 1			Level 2			Level 3			Total
	Assets
	Money market accounts	$	26,530		$	—		$	—		$	26,530

	Total Assets	$	26,530		$	—		$	—		$	26,530

	Liabilities
	Warrants		—			—			—			—

	Total Liabilities	$	—		$	—		$	—		$	—


	Fair value measurements using: (000’s) as of December 31, 2013
		Level 1			Level 2			Level 3			Total
	Assets
	Money market accounts	$	7,572		$	—		$	—		$	7,572

	Total Assets	$	7,572		$	—		$	—		$	7,572

	Liabilities
	Contingent Consideration	$	—		$	—		$	—		$	—
	Warrants		—			—			3,986			3,986

	Total Liabilities	$	—		$	—		$	3,986		$	3,986

Summary of Changes in the Fair Value of Warrants	The following table provides a summary of changes in the fair value of the warrants during the period are as follows (in thousands):



	Warrants	Amount
	Balance as of December 31, 2012	$	1,538
	Loss from change in fair value of warrant		2,448

	Balance as of December 31, 2013		3,986
	Gain from change in fair value of warrant		(1,835	)
	Warrant exercise		(2,151	)

	Balance as of December 31, 2014	$	—

Acquisition_of_the_assets_of_D1

Acquisition of the assets of DermEbx and Radion (Tables)	12 Months Ended
Acquisition of the assets of DermEbx and Radion (Tables)	Dec. 31, 2014
Business Combinations [Abstract]
Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed	The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition and the amortizable lives of the intangible assets:



		Amount			Estimated Amortizable Life
	Current assets	$	3,457
	Property and equipment		2,625			3–7 Years
	Identifiable intangible assets		6,050			5–10 Years
	Goodwill		6,154
	Current liabilities		(4,316	)
	Long-term liabilities		(2,114	)

	Purchase price	$	11,856

Summary of Unaudited Proforma Operating Results, Acquisition	The unaudited proforma operating results for the Company for the years ended December 30, 2014 and 2013, respectively assuming the acquisition of the assets of DermEbx and Radion occurred as of January 1, 2013 are as follows (in thousands except per share amounts):



		31-Dec
		2014			2013
	Revenue	$	48,145		$	35,639
	Income (loss) from operations		2,518			(5,402	)
	Net income (loss)		538			(11,376	)
	Basic net income (loss) per share	$	0.04		$	(1.05	)
	Diluted net income (loss) per share		0.04			(1.05	)
	Basic shares		14,096			10,842
	Diluted shares		15,097			10,842

Financing_Arrangements_Tables

Financing Arrangements (Tables)	12 Months Ended
Financing Arrangements (Tables)	Dec. 31, 2014
Debt Disclosure [Abstract]
Amount Related to Facility and Revenue Purchase Agreements	The following amounts are included in the consolidated balance sheet as of December 31, 2014 and 2013, respectively related to the Facility and Revenue Purchase agreements:



		December 31, 2014			December 31, 2013
	Principal Amount of Facility Agreement	$	15,000		$	15,000
	Unamortized discount		(1,898	)		(3,116	)
	Principal repayment		(3,750	)		—

	Carrying amount of Facility Agreement		9,352			11,884

	Revenue Purchase Agreement		—			3,636

	Less current portion of Facility Agreement		(3,750	)		(3,750	)

	Notes payable long-term portion	$	5,602		$	11,770

Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense in our consolidated statement of operations for the years ended December 31, 2014 and 2013:



		December 31, 2014			December 31, 2013
	Cash interest expense	$	1,271		$	2,155
	Non-cash amortization of debt discount		1,053			674
	Amortization of debt costs		110			182
	Amortization of settlement obligations		206			266

	Total interest expense	$	2,640		$	3,277

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consist of the following at December 31, (in thousands):



		2014		2013
	Accrued salary and related expenses	$	2,518	$	2,020
	Accrued accounts payable		1,589		1,012
	Accrued professional fees		414		284
	Accrued short term settlement costs		698		221
	Other accrued expenses		287		216
	Deferred rent		48		46

		$	5,554	$	3,799

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2014
Equity [Abstract]
Summary of Stock Option Activity for all Stock Option Plans	A summary of stock option activity for all stock option plans is as follows:



		Number of			Weighted Average			Weighted Average
		Shares			Exercise Price			Remaining
								Contractual Term
	Outstanding, January 1, 2012		1,080,722		$	9.75
	Granted		693,601		$	2.43
	Exercised		—		$	0
	Forfeited		(339,378	)	$	15.95

	Outstanding, December 31, 2012		1,434,945		$	4.75
	Granted		46,537		$	5.42
	Exercised		(48,427	)	$	3
	Forfeited		(98,100	)	$	11.62

	Outstanding, December 31, 2013		1,334,955		$	4.34
	Granted		281,043		$	8.08
	Exercised		(162,528	)	$	4.36
	Forfeited		(35,583	)	$	13.62

	Outstanding, December 31, 2014		1,417,887		$	4.84			6.6 years

	Exercisable at December 31, 2012		485,553		$	7.06

	Exercisable at December 31, 2013		743,910		$	5.09

	Exercisable at December 31, 2014		955,210		$	4.43			5.8 years

Stock-Based Compensation Expense Including Options and Restricted Stock by Category	The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands):



		Years Ended December 31,
		2014			2013			2012
	Cost of revenue	$	13		$	21		$	15
	Engineering and product development		165			228			178
	Marketing and sales		353			273			242
	General and administrative expense		787			680			561

		$	1,318		$	1,202		$	996

Options Granted under the Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values:



		Years Ended December 31,
		2014			2013			2012
	Average risk-free interest rate		0.85%			0.53%			0.98%
	Expected dividend yield		None			None			None
	Expected life		3.5 years			3.5 years			3.5 years
	Expected volatility		64.2% to 69.4%			57.6% to 68.9%			65.9% to 68.9%
	Weighted average exercise price	$	8.09		$	5.42		$	2.43
	Weighted average fair value	$	3.84		$	2.35		$	1.17
Summary of Restricted Stock Activity for All Equity Incentive Plans	A summary of restricted stock activity for all equity incentive plans is as follows:



		Years Ended December 31,
		2014			2013			2012
	Beginning outstanding balance		216,250			67,075			122,795
	Granted		180,500			196,250			—
	Vested		(85,434	)		(47,008	)		(47,820	)
	Forfeited		(1,999	)		(67	)		(7,900	)

	Ending outstanding balance		309,317			216,250			67,075

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	The components of income tax expense for the years ended December 31, 2014, 2013 and 2012 are as follows (in thousands):



		2014			2013			2012
	Current provision (benefit):
	Federal	$	(44	)	$	—		$	—
	State		118			126			43

		$	74		$	126		$	43

	Deferred provision:
	Federal	$	65		$	—		$	—
	State		14			—			—

		$	79		$	—		$	—

	Total	$	153		$	126		$	43

Summary of Effective and the Federal Statutory Income Tax Rate	A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31, 2014, 2013 and 2012 is as follows:



		2014			2013			2012
	Federal statutory rate		34	%		34	%		34	%
	State income taxes, net of federal benefit		5.5	%		2.3	%		4	%
	Net state impact of deferred rate change		13	%		0.1	%		0.1	%
	Stock compensation expense		(9.6	%)		(2.0	%)		(1.8	%)
	Tax amortization on goodwill		(9.0	%)		0	%		0	%
	Loss on warrant		71.6	%		0	%		0	%
	Other permanent differences		(1.1	%)		(11.7	%)		(2.4	%)
	Change in valuation allowance		(222.6	%)		(27.6	%)		(34.4	%)
	Tax credits		100.8	%		3.3	%		0	%

	Effective income tax		(17.4	%)		(1.6	%)		(0.5	%)

Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) are comprised of the following at December 31 (in thousands):



		2014			2013
	Inventory (Section 263A)	$	191		$	233
	Inventory reserves		106			156
	Receivable reserves		197			29
	Other accruals		887			938
	Deferred revenue		1,142			1,256
	Accumulated depreciation/amortization		65			(2	)
	Stock options		2,252			2,070
	Developed technology		(2,941	)		(3,464	)
	Tax credits		3,054			2,176
	NOL carryforward		34,690			34,059

	Net deferred tax assets		39,643			37,451
	Valuation allowance		(39,643	)		(37,451	)
	Goodwill tax amortization		(79	)		—

	Deferred tax liability	$	(79	)	$	—

Segment_Reporting_Geographical1

Segment Reporting, Geographical Information and Major Customers (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands, including prior periods which have been presented for consistency):



		Year Ended December 31,
		2014			2013			2012
	Segment revenues:
	Detection	$	18,604		$	16,905		$	17,262
	Therapy		25,320			16,162			11,013

	Total Revenue	$	43,924		$	33,067		$	28,275

	Segment gross profit:
	Detection	$	15,276		$	13,576		$	13,936
	Therapy		15,951			9,509			6,095

	Segment gross profit	$	31,227		$	23,085		$	20,031

	Segment operating income (loss):
	Detection	$	7,231		$	5,016		$	4,274
	Therapy		1,868			(52	)		(2,720	)

	Segment operating income	$	9,099		$	4,964		$	1,554

	General, administrative, depreciation and amortization expense	$	(8,284	)	$	(6,740	)	$	(6,966	)
	Interest expense		(2,640	)		(3,277	)		(3,415	)
	Gain on fair value of warrant		1,835			(2,448	)		(539	)
	Other income		37			19			35
	Loss on debt extinguishment		(903	)		—			—

	Loss before income tax	$	(856	)	$	(7,482	)	$	(9,331	)

Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss)	Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands):



	Detection depreciation and amortization
	Depreciation		188			175			144
	Amortization		515			517			519
	Therapy depreciation and amortization
	Depreciation		844			424			595
	Amortization		1,739			939			931

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Rental Payments	Future minimum rental payments due under these agreements as of December 31, 2014 are as follows (in thousands):


	Fiscal Year	Operating
	Fiscal Year	Leases
	2015		482
	2016		490
	2017		255

		$	1,227

Future Minimum Lease Payments under Non-cancelable Capital Leases	Future minimum lease payments under this lease are as follows:


	Fiscal Year	Capital Leases
	2015		1,513
	2016		1,004
	2017		89

	subtotal minimum lease obligation		2,606
	less interest		(292	)

	Total, net		2,314
	less current portion		(1,294	)

	long term portion	$	1,020

Quarterly_Financial_Data_Table

Quarterly Financial Data (Tables)	12 Months Ended
Quarterly Financial Data (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data		Net		Gross		Net			Income (loss)			Weighted
		sales		profit		income (loss)			per share			average
												number of
												shares outstanding
	2014
	First quarter	$	8,520	$	5,934	$	(190	)	($	0.02	)		11,429
	Second quarter		9,667		6,830	$	(997	)	($	0.07	)		14,074
	Third quarter		12,572		9,167	$	274		$	0.02			15,283
	Fourth quarter		13,165		9,296	$	(96	)	($	0.01	)		15,541
	2013
	First quarter	$	7,930	$	5,648	$	(727	)	($	0.07	)		10,820
	Second quarter		7,712		5,222	$	(1,882	)	($	0.17	)		10,836
	Third quarter		8,290		5,926	$	(589	)	($	0.05	)		10,849
	Fourth quarter		9,135		6,289	$	(4,410	)	($	0.41	)		10,863

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended				0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Apr. 30, 2014	Dec. 31, 2010	Dec. 31, 2001
	Segment	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Apr. 30, 2014	Dec. 31, 2010	Dec. 31, 2001
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business segment	2
Maturity for cash and cash equivalents	90 days
Insurance coverage	$250,000
Interest-bearing amounts on deposit in excess of federally	31,100,000
Impairment losses on long lived assets	0	0	0
Amortization expense related to intangible assets	2,270,000	1,724,000	1,904,000
Percentage of discount derived from capital asset pricing model	17.00%
Long term warranty obligations	5,000	8,000		10,000
Advertising expense	882,000	639,000	762,000
Contingent consideration liability		0				5,000,000
Number of common stock shares issued					450,000
Gain from warrant exercise	-1,835,000	2,448,000	539,000
Goodwill impairment				26,800,000
Warrants [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Warrant value					2,151,000
Gain from warrant exercise					699,000
Deerfield Agreement [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Warrant or right exercisable				550,000	450,000		100,000
Aggregate purchase price of warrants					1,575,000
Number of common stock shares cancelled					100,000
Detection [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Amortization expense related to intangible assets	515,000	517,000	519,000
Percentage of fair value of each reporting unit	315.00%
Therapy [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Amortization expense related to intangible assets	$1,739,000	$939,000	$931,000
Percentage of fair value of each reporting unit	255.00%
Minimum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets	5 years
Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets	15 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]
Balance at beginning of period	$73	$48	$54
Additions charged to costs and expenses	167	35
Reductions	-37	-10	-6
Balance at end of period	$203	$73	$48

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Current Inventory (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Raw materials	$955	$581
Work in process	54	38
Finished Goods	1,205	1,272
Inventory	$2,214	$1,891

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2014
Minimum [Member] \| Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] \| Marketing Assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Maximum [Member] \| Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] \| Marketing Assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Schedule of Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Gross Carrying Amount
Gross Carrying Amount	$32,242	$26,142
Accumulated Amortization
Accumulated Amortization	14,738	12,468
Total amortizable intangible assets, net	17,504	13,674
Patents and Licenses [Member]
Gross Carrying Amount
Gross Carrying Amount	767	737
Weighted average useful life	5 years
Accumulated Amortization
Accumulated Amortization	517	471
Technology [Member]
Gross Carrying Amount
Gross Carrying Amount	25,639	24,909
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	13,076	11,589
Customer Relationships [Member]
Gross Carrying Amount
Gross Carrying Amount	5,548	248
Weighted average useful life	7 years
Accumulated Amortization
Accumulated Amortization	896	160
Tradename [Member]
Gross Carrying Amount
Gross Carrying Amount	288	248
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	$249	$248

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Schedule of Expected Amortization Expense (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
2015	$3,095
2016	2,462
2017	2,254
2018	1,934
2019	1,659
Thereafter	6,100
Total amortizable intangible assets, net	$17,504	$13,674

Summary_of_Significant_Account9

Summary of Significant Accounting Policies - Roll Forward of Goodwill Activity by Reportable Segment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Line Items]
Accumulated Goodwill	$47,937
Accumulated impairment	-26,828
Goodwill Balance		21,109
Goodwill Balance	27,263	21,109
DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisitions of DermEbx and Radion	6,154
Detection [Member]
Goodwill [Line Items]
Fair value allocation	7,663
Goodwill Balance	7,663
Goodwill Balance	7,663
Therapy [Member]
Goodwill [Line Items]
Fair value allocation	13,446
Goodwill Balance	13,446
Goodwill Balance	19,600
Therapy [Member] \| DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisitions of DermEbx and Radion	$6,154

Recovered_Sheet1

Summary of Significant Accounting Policies - Roll Forward of Warranty Cost (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Beginning accrual balance	$25	$36	$89
Warranty provision	58	96	37
Usage	-69	-107	-90
Ending accrual balance	$14	$25	$36

Recovered_Sheet2

Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss available to common shareholders	($96)	$274	($997)	($190)	($4,410)	($589)	($1,882)	($727)	($1,009)	($7,608)	($9,374)
Basic shares used in the calculation of earnings per share									14,096	10,842	10,796
Effect of dilutive securities:
Diluted shares used in the calculation of earnings per share									14,096	10,842	10,796
Basic									($0.07)	($0.70)	($0.87)
Diluted									($0.07)	($0.70)	($0.87)
Stock Options [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements
Restricted Stock [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements

Recovered_Sheet3

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,727,204	2,101,205	2,052,020
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,417,887	1,334,955	1,434,945
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock		550,000	550,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	309,317	216,250	67,075

Recovered_Sheet4

Summary of Significant Accounting Policies - Schedule of Fair Value of Warrants (Detail) (Warrants [Member], USD $)	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Dec. 31, 2013
Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price	$3.50	$3.50
Volatility	40.80%	56.20%
Equivalent term (years)	0 years	4 years
Risk-free interest rate	0.10%	1.30%

Recovered_Sheet5

Summary of Significant Accounting Policies - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Assets
Total Assets	$26,530	$7,572
Liabilities
Total Liabilities		3,986
Money Market Accounts [Member]
Assets
Total Assets	26,530	7,572
Warrants [Member]
Liabilities
Total Liabilities		3,986
Level 1 [Member]
Assets
Total Assets	26,530	7,572
Level 1 [Member] \| Money Market Accounts [Member]
Assets
Total Assets	26,530	7,572
Level 3 [Member]
Liabilities
Total Liabilities		3,986
Level 3 [Member] \| Warrants [Member]
Liabilities
Total Liabilities		$3,986

Recovered_Sheet6

Summary of Significant Accounting Policies - Summary of Changes in the Fair Value of Warrants (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]
Beginning Balance	$3,986	$1,538
Gain (Loss) from change in fair value of warrant	-1,835	2,448	539
Warrant exercise	-2,151
Ending Balance		$3,986	$1,538

Acquisition_of_the_assets_of_D2

Acquisition of the assets of DermEbx and Radion - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jul. 15, 2014

Business Acquisition [Line Items]

Common stock, par value

$0.01

Goodwill deductible for income tax purposes

$27,263,000

$21,109,000

$27,263,000

$21,109,000

Revenue

13,165,000

12,572,000

9,667,000

8,520,000

9,135,000

8,290,000

7,712,000

7,930,000

43,924,000

33,067,000

28,275,000

Radion Inc [Member]

Business Acquisition [Line Items]

Business acquisition paid in cash

2,382,000

Restricted shares provisions description

The 600,000 restricted shares are subject to the following provisions; 25% shall be locked up until the date that is two trading days after the Company announces its fourth quarter 2014 earnings; 30% of the shares shall be locked up for a period of twenty-four (24) months from the date of the agreement; and 30% of the shares shall be locked up for a period of thirty-six (36) months from the date of the agreement.

Percentage of restricted shares held in escrow

15.00%

Restricted shares held in escrow

90,000

Restricted shares held in escrow, period

18 months

Repayment of note payable

182,000

Goodwill deductible for income tax purposes

6,200,000

6,154,000

Radion Inc [Member] | Restricted Stock [Member] | Common Stock [Member]

Business Acquisition [Line Items]

Business acquisition restricted shares issued

600,000

DermEbx [Member]

Business Acquisition [Line Items]

Business acquisition paid in cash

1,600,000

Cash consideration held back for purpose of purchase price adjustment

500,000

Restricted shares provisions description

Percentage of restricted shares held in escrow

15.00%

Restricted shares held in escrow

90,000

Restricted shares held in escrow, period

18 months

DermEbx [Member] | Restricted Stock [Member]

Business Acquisition [Line Items]

Common stock, par value

$0.01

DermEbx [Member] | Restricted Stock [Member] | Common Stock [Member]

Business Acquisition [Line Items]

Business acquisition restricted shares issued

600,000

DermEbx and Radion [Member]

Business Acquisition [Line Items]

Revenue

$7,900,000

Acquisition_of_the_assets_of_D3

Acquisition of the assets of DermEbx and Radion - Preliminary Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) (USD $)	12 Months Ended	0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Jul. 15, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill	27,263		$21,109
Radion Inc [Member]
Business Acquisition [Line Items]
Current assets		3,457
Property and equipment		2,625
Identifiable intangible assets		6,050
Goodwill	6,200	6,154
Current liabilities		-4,316
Long-term liabilities		-2,114
Purchase price		11,856
Minimum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	5 years
Minimum [Member] \| Radion Inc [Member]
Business Acquisition [Line Items]
Property and equipment, Estimated amortizable life		3 years
Estimated amortizable life		5 years
Maximum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	15 years
Maximum [Member] \| Radion Inc [Member]
Business Acquisition [Line Items]
Property and equipment, Estimated amortizable life		7 years
Estimated amortizable life		10 years

Acquisition_of_the_assets_of_D4

Acquisition of the assets of DermEbx and Radion - Summary of Unaudited Proforma Operating Results, Acquisition (Detail) (DermEbx and Radion [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
DermEbx and Radion [Member]
Business Acquisition [Line Items]
Revenue	$48,145	$35,639
Income (loss) from operations	2,518	-5,402
Net income (loss)	538	-11,386
Basic net income (loss) per share	$0.04	($1.05)
Diluted net income (loss) per share	$0.04	($1.05)
Basic shares	14,096	10,842
Diluted shares	$15,097	$10,842

Financing_Arrangements_Additio

Financing Arrangements - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended
	Apr. 30, 2014	Dec. 31, 2014	Oct. 29, 2014	Dec. 31, 2013	Dec. 31, 2011
Financing Arrangements [Line Items]
Percentage of revenue under condition one		4.25%
Percentage of revenue under condition four		1.00%
Amount of revenue under condition one		25 and Less
Amount of revenue under condition two		25 to 50
Amount of revenue under condition three		50 and Above
Number of common stock shares issued	450,000
Aggregate purchase price of warrants	$1,575,000
Common stock, shares issued	450,000	15,732,177		11,084,119
Cancellation of warrants to purchase number of additional shares of common stock		100,000
Warrants [Member]
Financing Arrangements [Line Items]
Number of common stock shares issued		550,000
Exercise price of warrants		3.5
2013 [Member]
Financing Arrangements [Line Items]
Percentage of revenue under condition two due in year one and two		2.75%
2014 [Member]
Financing Arrangements [Line Items]
Percentage of revenue under condition two due in year one and two		2.75%
2015 [Member]
Financing Arrangements [Line Items]
Percentage of revenue under condition three due in year three and four		2.25%
2016 [Member]
Financing Arrangements [Line Items]
Percentage of revenue under condition three due in year three and four		2.25%
2017 [Member]
Financing Arrangements [Line Items]
Percentage of revenue under condition three due in year three and four		2.25%
Revenue Purchase Agreement [Member]
Financing Arrangements [Line Items]
Interest on facility agreement		5.75%
Facility Agreement [Member]
Financing Arrangements [Line Items]
Interest on facility agreement		5.75%
Revenue Purchase Agreement [Member]
Financing Arrangements [Line Items]
Payment for termination of agreement	4,100,000
recorded loss in connection with termination agreement		900,000
December 2014 [Member] \| Facility Agreement [Member]
Financing Arrangements [Line Items]
Repayment of debt		3,750,000
Long term debt maturities repayment terms		Dec-14
December 2015 [Member] \| Facility Agreement [Member]
Financing Arrangements [Line Items]
Repayment of debt		3,750,000
Long term debt maturities repayment terms		Dec-15
December 2016 [Member] \| Facility Agreement [Member]
Financing Arrangements [Line Items]
Repayment of debt		7,500,000
Long term debt maturities repayment terms		Dec-16
Extended final repayment of debt		3,750,000
December 2017 [Member] \| Facility Agreement [Member]
Financing Arrangements [Line Items]
Extended final repayment of debt		3,750,000
Deerfield Agreement [Member]
Financing Arrangements [Line Items]
Amount provided in funding to company					15,000,000
Deerfield Agreement [Member] \| December 2014 [Member]
Financing Arrangements [Line Items]
Repayment of debt			$3,750,000

Financing_Arrangements_Amount_

Financing Arrangements - Amount Related to Facility and Revenue Purchase Agreements (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Credit Facility [Line Items]
Less current portion of Facility Agreement	($3,750)	($3,750)
Notes payable long-term portion	5,602	11,770
Facility Agreement [Member]
Credit Facility [Line Items]
Principal amount of Facility Agreement	15,000	15,000
Unamortized discount	-1,898	-3,116
Principal repayment	-3,750
Carrying amount of Facility Agreement	9,352	11,884
Revenue Purchase Agreement [Member]
Credit Facility [Line Items]
Principal amount of Facility Agreement		$3,636

Financing_Arrangements_Interes

Financing Arrangements - Interest Expense in Consolidated Income Statement (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Interest Expense, Debt [Abstract]
Cash interest expense	$1,271	$2,155
Non-cash amortization of debt discount	1,053	674
Amortization of debt costs	110	182
Amortization of settlement obligations	206	266	388
Total interest expense	$2,640	$3,277	$3,415

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued salary and related expenses	$2,518	$2,020
Accrued accounts payable	1,589	1,012
Accrued professional fees	414	284
Accrued short term settlement costs	698	221
Other accrued expenses	287	216
Deferred rent	48	46
Accrued Expenses Total	$5,554	$3,799

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option	5
Available for future grants	666,348
Total unrecognized compensation costs	$2,200,000
Period of expected recognized over a weighted average	1 year 2 months 9 days
Dividends paid on common stock	0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	1 year
Aggregate intrinsic values of closing market price	$9.17	$11.66	$4.79
Aggregate intrinsic value of options outstanding	2,800,000	2,500,000	300,000
Aggregate intrinsic value of the options vested in period	800,000	500,000	200,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options outstanding	6,300,000	10,000,000	1,800,000
Aggregate intrinsic value of the options exercisable	4,600,000	5,100,000	300,000
Aggregate intrinsic value of stock options exercised	$1,000,000	$500,000	$0
Aggregate intrinsic values of closing market price	$9.17	$11.66	$4.79
2001 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	240,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of expiration	10 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
2001 Stock Option Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	6 months
2001 Stock Option Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	5 years
2002 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	100,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of expiration	10 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
2002 Stock Option Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	6 months
2002 Stock Option Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	5 years
2007 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,050,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Number of share options available for grant	28,854
Aggregate purchase of Company's common stock, maximum	160,000
2012 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,600,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Number of share options available for grant	627,721
Aggregate purchase of Company's common stock, maximum	250,000
2004 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of options granted	5 years
Period of expiration	10 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	200,000
2005 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	120,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of options granted	3 years
Period of expiration	5 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	9,773

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity for all Stock Option Plans (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning balance	1,334,955	1,434,945	1,080,722
Granted	281,043	46,537	693,601
Exercised	-162,528	-48,427
Forfeited	-35,583	-98,100	-339,378
Ending balance	1,417,887	1,334,955	1,434,945
Weighted Average, Beginning Balance	$4.34	$4.75	$9.75
Granted	$8.08	$5.42	$2.43
Exercised	$4.36	$3	$0
Forfeited	$13.62	$11.62	$15.95
Weighted Average, Ending Balance	$4.84	$4.34	$4.75
Exercisable, Number of Shares	955,210	743,910	485,553
Exercisable, Weighted Average Exercise Price	$4.43	$5.09	$7.06

Stockholders_Equity_StockBased

Stockholders' Equity - Stock-Based Compensation Expense by Categories (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$1,318	$1,202	$996
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	13	21	15
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	165	228	178
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	353	273	242
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$787	$680	$561

Stockholders_Equity_Options_Gr

Stockholders' Equity - Options Granted Under the Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price	$8.08	$5.42	$2.43
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	0.85%	0.53%	0.98%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price	$8.09	$5.42	$2.43
Weighted average fair value	$3.84	$2.35	$1.17
Minimum [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	64.20%	57.60%	65.90%
Maximum [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	69.40%	68.90%	68.90%

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Restricted Stock Activity for All Equity Incentive Plans (Detail) (Restricted Stock [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning outstanding balance	216,250	67,075	122,795
Granted	180,500	196,250
Vested	-85,434	-47,008	-47,820
Forfeited	-1,999	-67	-7,900
Ending outstanding balance	309,317	216,250	67,075

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current provision (benefit):
Federal	($44)
State	118	126	43
Current provision (benefit), Total	74	126	43
Deferred provision:
Federal	65
State	14
Deferred provision, Total	79	0
Total	$153	$126	$43

Income_Taxes_Summary_of_Effect

Income Taxes - Summary of Effective And the Federal Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal statutory rate	34.00%	34.00%	34.00%
State income taxes, net of federal benefit	5.50%	2.30%	4.00%
Net state impact of deferred rate change	13.00%	0.10%	0.10%
Stock compensation expense	-9.60%	-2.00%	-1.80%
Tax amortization on goodwill	-9.00%	0.00%	0.00%
Loss on warrant	71.60%	0.00%	0.00%
Other permanent differences	-1.10%	-11.70%	-2.40%
Change in valuation allowance	-222.60%	-27.60%	-34.40%
Tax credits	100.80%	3.30%	0.00%
Effective income tax	-17.40%	-1.60%	-0.50%

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets (Liabilities) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Inventory (Section 263A)	$191	$233
Inventory reserves	106	156
Receivable reserves	197	29
Other accruals	887	938
Deferred revenue	1,142	1,256
Accumulated depreciation/amortization	65	-2
Stock options	2,252	2,070
Developed technology	-2,941	-3,464
Tax credits	3,054	2,176
NOL carryforward	34,690	34,059
Net deferred tax assets	39,643	37,451
Valuation allowance	-39,643	-37,451
Goodwill tax amortization	-79
Deferred tax liability	($79)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Income Tax Expense [Line Items]
NOL carryforward	$95,600,000
Total net operating loss carryforward	34,690,000	34,059,000
Net operating losses	815,000	-1,776,000	-5,412,000
Adjustment to liabilities or operations	79,000	0
Operating losses carryforwards	13,800,000
Net operating losses	2,000,000
Future Income tax liabilities offset With operation loss carryforward	3,100,000
Tax credit carryforwards	5,800,000
Tax credit carryforward expiration year	2034
Unrecognized tax benefits	0	0
Xoft Inc [Member]
Schedule Of Income Tax Expense [Line Items]
Tax credit carryforwards	1,800,000
Deferred tax assets	0
Xoft Inc [Member]
Schedule Of Income Tax Expense [Line Items]
Total net operating loss carryforward	25,200,000
Net operating losses	0	0
Xoft, Inc. Acquisition [Member]
Schedule Of Income Tax Expense [Line Items]
Operating losses carryforwards	9,500,000
Net operating losses	$473,000
Minimum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward	2016
Maximum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward	2034

Segment_Reporting_Geographical2

Segment Reporting, Geographical Information and Major Customers - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
									Segment
									Customer
Schedule Of Geographical Information [Line Items]
Number of reporting segments									2
Total Export Sales	$13,165,000	$12,572,000	$9,667,000	$8,520,000	$9,135,000	$8,290,000	$7,712,000	$7,930,000	$43,924,000	$33,067,000	$28,275,000
Percentage of export sales to any single country									10.00%
Number of major customers									1
GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	1,300,000								1,300,000
Two Customers [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	900,000								900,000
Oem [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	1,900,000								1,900,000
Six Customers [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	2,900,000								2,900,000
Detection [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales									18,604,000	16,905,000	17,262,000
Intersegment Eliminations [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales									0
Sales [Member] \| GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Total revenue									4,100,000	3,700,000	4,500,000
Sales [Member] \| Customer Concentration Risk [Member] \| GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									9.40%	11.00%	16.00%
Sales [Member] \| Customer Concentration Risk [Member] \| Four Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									22.00%
Sales [Member] \| Detection [Member] \| Customer Concentration Risk [Member] \| Four Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									53.00%
Accounts Receivable [Member] \| GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									15.00%
Accounts Receivable [Member] \| Two Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									10.00%
Accounts Receivable [Member] \| Oem [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									22.00%
Accounts Receivable [Member] \| Six Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									33.00%
Foreign [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales									1,800,000	1,900,000	2,900,000
Percentage of export sales of total sale									4.00%	6.00%	10.00%
Outstanding receivables	$300,000				$300,000				$300,000	$300,000

Segment_Reporting_Summary_of_S

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment revenues:
Total revenue	$13,165,000	$12,572,000	$9,667,000	$8,520,000	$9,135,000	$8,290,000	$7,712,000	$7,930,000	$43,924,000	$33,067,000	$28,275,000
Segment gross profit	9,296,000	9,167,000	6,830,000	5,934,000	6,289,000	5,926,000	5,222,000	5,648,000	31,227,000	23,085,000	20,031,000
Segment operating income (loss):
Segment operating income									815,000	-1,776,000	-5,412,000
General, administrative, depreciation and amortization expense									-8,284,000	-6,740,000	-6,966,000
Interest expense									-2,640,000	-3,277,000	-3,415,000
Gain on fair value of warrant									1,835,000	-2,448,000	-539,000
Other income									37,000	19,000	35,000
Loss on debt extinguishment									-903,000
Loss before income tax expense									-856,000	-7,482,000	-9,331,000
Detection [Member]
Segment revenues:
Total revenue									18,604,000	16,905,000	17,262,000
Segment gross profit									15,276,000	13,576,000	13,936,000
Segment operating income (loss):
Segment operating income									7,231,000	5,016,000	4,274,000
Therapy [Member]
Segment revenues:
Total revenue									25,320,000	16,162,000	11,013,000
Segment gross profit									15,951,000	9,509,000	6,095,000
Segment operating income (loss):
Segment operating income									1,868,000	-52,000	-2,720,000
All Reporting Segments [Member]
Segment operating income (loss):
Segment operating income									$9,099,000	$4,964,000	$1,554,000

Segment_Reporting_Geographical3

Segment Reporting, Geographical Information and Major Customers - Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	$1,256	$706	$891
Amortization	2,270	1,724	1,904
Detection [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	188	175	144
Amortization	515	517	519
Therapy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	844	424	595
Amortization	$1,739	$939	$931

Commitment_and_Contingencies_A

Commitment and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2010	Jul. 31, 2007	Dec. 31, 2015	Aug. 31, 2013
	Lease
	sqft
Loss Contingencies [Line Items]
Lease obligations	3
Annual base rent for the first year	$1,513,000
Rent for the second year	1,004,000
Rent for the third year	89,000
Operating lease, annual base rent, first year	482,000
Operating lease, annual rent, second year	490,000
Operating lease, annual rent, third year	255,000
Rent expense	643,000	697,000	799,000
Capital lease							409,000
Capital lease agreement interest percentage							3.99%
Capital lease bargain purchase option amount							1
Remaining purchase obligation							200,000
Outstanding liability on equipment leases	1,020,000	235,000
Purchase obligations to suppliers for future product deliverables	1,000,000
Minimum annual royalty payment	250,000
Fair value of patent license	100,000
Patent license, Estimated Amortizable Life	4 years
Minimum royalty obligations	600,000
Estimated value of liability	800,000
Jun-15	500,000
Jun-17	500,000
Litigation and settlement obligation, Total	1,000,000
Area of office, manufacturing and warehousing space	24,250
Employer matching Contribution	400,000
Employer matching Contribution to be paid in next fiscal year						500,000
CADx Medical Systems Inc. [Member]
Loss Contingencies [Line Items]
Tax re-assessment received					6,800,000
Reduced tax re-assessment received				703,000
DermEbx and Radion [Member]
Loss Contingencies [Line Items]
Number of equipment lease obligation	2
Assumed capital leases	2,600,000
Liability recorded on capital leases	2,500,000
Outstanding liability on equipment leases	2,100,000
Nashua [Member]
Loss Contingencies [Line Items]
Term of lease	5 years
Annual base rent for the first year	181,764
Rent for the second year	187,272
Rent for the third year	192,780
Rent for the fourth year	198,288
Rent for the fifth year	203,796
Additional period to extend term of lease	5 years
San Jose California [Member]
Loss Contingencies [Line Items]
Operating lease, annual base rent, first year	248,376
Operating lease, annual rent, second year	260,064
Operating lease, annual rent, third year	271,752
Operating lease, annual rent, fourth year	283,440
Operating lease, annual rent, fifth year	$295,140
Lease extension period	0

Commitments_and_Contingencies_1

Commitments and Contingencies - Future Minimum Rental Payments (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$482
2016	490
2017	255
Total	$1,227

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments under Non-cancelable Capital Leases (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
2015	$1,513
2016	1,004
2017	89
subtotal minimum lease obligation	2,606
less interest	-292
Total, net	2,314
less current portion	-1,294
long term portion	$1,020	$235

Quarterly_Financial_Data_Quart

Quarterly Financial Data - Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net sales	$13,165	$12,572	$9,667	$8,520	$9,135	$8,290	$7,712	$7,930	$43,924	$33,067	$28,275
Gross profit	9,296	9,167	6,830	5,934	6,289	5,926	5,222	5,648	31,227	23,085	20,031
Net income (loss)	($96)	$274	($997)	($190)	($4,410)	($589)	($1,882)	($727)	($1,009)	($7,608)	($9,374)
Loss per share available to common stockholders	($0.01)	$0.02	($0.07)	($0.02)	($0.41)	($0.05)	($0.17)	($0.07)
Weighted average number of shares outstanding	15,541	15,283	14,074	11,429	10,863	10,849	10,836	10,820